1
|
Curtis JR, Yun H, Chen L, Ford SS, van Hoogstraten H, Fiore S, Ford K, Praestgaard A, Rehberg M, Choy E. Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry. Rheumatol Ther 2024; 11:217. [PMID: 37955805 PMCID: PMC10796306 DOI: 10.1007/s40744-023-00607-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2023] Open
Affiliation(s)
- Jeffrey R Curtis
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
| | - Huifeng Yun
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - Lang Chen
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | | | | | | | | | | | | | - Ernest Choy
- CREATE Centre, Cardiff University, Cardiff, UK
| |
Collapse
|
2
|
Curtis JR, Ford K, Fiore S, Mikuls TR, Shaney K, Sethi V. Development of an Interactive Tool to Support Shared Decision-Making in Rheumatoid Arthritis: Treatment Attribute Preference. Arthritis Care Res (Hoboken) 2024; 76:181-190. [PMID: 37652871 DOI: 10.1002/acr.25223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 08/03/2023] [Accepted: 08/24/2023] [Indexed: 09/02/2023]
Abstract
OBJECTIVE An interactive tool identifying treatment attributes important to patients can enhance shared decision-making (SDM) in rheumatoid arthritis (RA). A formative survey was conducted to identify the most important treatment attributes from patients' perspective, which can be used to develop an interactive SDM tool. METHODS The survey was performed in two phases: qualitative interviews and quantitative surveys. The qualitative interviews were conducted to inform the design of the quantitative survey. In qualitative interviews, patients with RA (n = 10) and rheumatologists (n = 10) were introduced to the SDM tool concept. Feedback on the design and scope of the SDM tool was used to develop a quantitative survey, conducted in a large sample size of patients. Patient preferences for treatment attributes (route of administration and dosing frequency, serious side effects, out-of-pocket costs, efficacy, and monitoring requirement) were assessed via adaptive conjoint exercise involving ranking of hypothetical RA treatment configurations. RESULTS A total of 944 patients (males: 43%, females: 57%) with RA participated in the quantitative survey. Route of administration and dosing frequency (38%) followed by serious side effects (33%) were the two most important treatment attributes for individual patients. The recontact survey (n = 172/944) estimated tool stability of 72% (n = 124/172) in terms of the relative importance of treatment attributes. CONCLUSION The findings of this survey could be used in the development of an SDM tool that can potentially provide insights into patient preferences and is generally well received by patients and rheumatologists with good agreement and reliability.
Collapse
Affiliation(s)
| | | | | | - Ted R Mikuls
- University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska
| | | | | |
Collapse
|
3
|
Dua AB, Ford K, Fiore S, Pappas DA, Janak JC, Blachley T, Roberts-Toler C, Emeanuru K, Kremer JM, Kivitz A. Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study. Rheumatol Ther 2023; 10:1753-1768. [PMID: 37906399 PMCID: PMC10654323 DOI: 10.1007/s40744-023-00609-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Accepted: 10/06/2023] [Indexed: 11/02/2023] Open
Abstract
INTRODUCTION This observational study evaluated response in patients with rheumatoid arthritis (RA) who switched from an interleukin-6 receptor inhibitor (IL-6Ri) to a Janus kinase inhibitor (JAKi) and vice versa. METHODS Adult patients with RA, who initiated IL-6Ri or JAKi (following discontinuation of JAKi or IL-6Ri, respectively) during/after December 2012 and had a 6-month follow-up visit were enrolled. Clinical outcomes were evaluated at baseline and the follow-up visit. Continuous outcomes included Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire (HAQ), pain, fatigue, tender joint count, swollen joint count, Physician Global Assessment (MDGA), Patient Global Assessment (PtGA), and morning stiffness duration. Categorical outcomes included the proportion of patients achieving CDAI low disease activity (LDA), remission, and minimal clinically important differences (MCIDs) for HAQ, pain, fatigue, MDGA, and PtGA. Continuous outcomes were summarized as mean changes from baseline, and categorical outcomes as response rates. Differences in the outcome measures between groups were evaluated using linear and logistic regression models. RESULTS Between IL-6Ri (n = 100) and JAKi initiators (n = 129), no significant differences were noted for continuous outcomes. Within both groups, a significant proportion of patients achieved LDA, remission, and MCIDs for other measures, although the odds of achieving LDA were higher among IL-6Ri (vs. JAKi) initiators with moderate-to-severe disease (adjusted odds ratio: 3.30 [1.01, 10.78]). CONCLUSIONS Patients with RA can achieve improvement in response when switching between IL-6Ri and JAKi. Although both therapies affect the IL-6 pathway, there are distinct mechanisms of action, which likely contribute to their clinical improvement, when reciprocally switched as follow-on treatments.
Collapse
Affiliation(s)
- Anisha B Dua
- Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
| | - Kerri Ford
- Medical Affairs, Sanofi, Cambridge, MA, USA
| | | | - Dimitrios A Pappas
- CorEvitas, LLC, Waltham, MA, USA
- Division of Rheumatology, Columbia University, New York, NY, USA
- Corrona Research Foundation, Waltham, MA, USA
| | | | | | | | | | - Joel M Kremer
- CorEvitas, LLC, Waltham, MA, USA
- Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, NY, USA
| | - Alan Kivitz
- Altoona Center for Clinical Research, Duncansville, PA, USA
| |
Collapse
|
4
|
Fedele G, Schiavoni I, Trentini F, Leone P, Olivetta E, Fallucca A, Fiore S, Di Martino A, Abrignani S, Baldo V, Baldovin T, Bandera A, Clerici P, De Paschale M, Diaco F, Domnich A, Fortunato F, Giberti I, Gori A, Grifantini R, Lazzarotto T, Lodi V, Mastroianni CM, Prato R, Restivo V, Vitale F, Brusaferro S, Merler S, Palamara AT, Stefanelli P. A 12-month follow-up of the immune response to SARS-CoV-2 primary vaccination: evidence from a real-world study. Front Immunol 2023; 14:1272119. [PMID: 38077369 PMCID: PMC10698351 DOI: 10.3389/fimmu.2023.1272119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 11/01/2023] [Indexed: 12/18/2023] Open
Abstract
A real-world population-based longitudinal study, aimed at determining the magnitude and duration of immunity induced by different types of vaccines against COVID-19, started in 2021 by enrolling a cohort of 2,497 individuals at time of their first vaccination. The study cohort included both healthy adults aged ≤65 years and elderly subjects aged >65 years with two or more co-morbidities. Here, patterns of anti-SARS-CoV-2 humoral and cell-mediated specific immune response, assessed on 1,182 remaining subjects, at 6 (T6) and 12 months (T12) after the first vaccine dose, are described. At T12 median anti-Spike IgG antibody levels were increased compared to T6. The determinants of increased anti-Spike IgG were the receipt of a third vaccine dose between T6 and T12 and being positive for anti-Nucleocapside IgG at T12, a marker of recent infection, while age had no significant effect. The capacity of T12 sera to neutralize in vitro the ancestral B strain and the Omicron BA.5 variant was assessed in a subgroup of vaccinated subjects. A correlation between anti-S IgG levels and sera neutralizing capacity was identified and higher neutralizing capacity was evident in healthy adults compared to frail elderly subjects and in those who were positive for anti-Nucleocapside IgG at T12. Remarkably, one third of T12 sera from anti-Nucleocapside IgG negative older individuals were unable to neutralize the BA.5 variant strain. Finally, the evaluation of T-cell mediated immunity showed that most analysed subjects, independently from age and comorbidity, displayed Spike-specific responses with a high degree of polyfunctionality, especially in the CD8 compartment. In conclusion, vaccinated subjects had high levels of circulating antibodies against SARS-CoV-2 Spike protein 12 months after the primary vaccination, which increased as compared to T6. The enhancing effect could be attributable to the administration of a third vaccine dose but also to the occurrence of breakthrough infection. Older individuals, especially those who were anti-Nucleocapside IgG negative, displayed an impaired capacity to neutralize the BA.5 variant strain. Spike specific T-cell responses, able to sustain immunity and maintain the ability to fight the infection, were present in most of older and younger subjects assayed at T12.
Collapse
Affiliation(s)
- Giorgio Fedele
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Ilaria Schiavoni
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Filippo Trentini
- Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy
- Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy
| | - Pasqualina Leone
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Eleonora Olivetta
- National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
| | - Alessandra Fallucca
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, Palermo, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Angela Di Martino
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Sergio Abrignani
- INGM, Istituto Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi”, Milan, Italy
- Department of Clinical Sciences & Community Health, University of Milan, Milan, Italy
| | - Vincenzo Baldo
- Laboratory of Hygiene and Applied Microbiology, Hygiene and Public Health Unit, Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Tatjana Baldovin
- Laboratory of Hygiene and Applied Microbiology, Hygiene and Public Health Unit, Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Alessandra Bandera
- Infectious Diseases Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan, Italy
| | - Pierangelo Clerici
- Microbiology Unit, Azienda Socio Sanitaria Territoriale (ASST) Ovest Milanese, Milan, Italy
| | - Massimo De Paschale
- Microbiology Unit, Azienda Socio Sanitaria Territoriale (ASST) Ovest Milanese, Milan, Italy
| | - Fabiana Diaco
- Department of Molecular Medicine, AOU Policlinico Umberto I, Sapienza University, Rome, Italy
| | - Alexander Domnich
- IRCCS Ospedale Policlinico San Martino Genova, and Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Francesca Fortunato
- Hygiene Unit, Policlinico Riuniti Foggia Hospital, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
| | - Irene Giberti
- IRCCS Ospedale Policlinico San Martino Genova, and Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Andrea Gori
- Microbiology Unit, Azienda Socio Sanitaria Territoriale (ASST) Ovest Milanese, Milan, Italy
- II Division of Infectious Diseases, "Luigi Sacco" Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Renata Grifantini
- INGM, Istituto Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi”, Milan, Italy
| | - Tiziana Lazzarotto
- Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Section of Microbiology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - Vittorio Lodi
- Occupational Health Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Claudio Maria Mastroianni
- Department of Public Health and Infectious Disease, AOU Policlinico Umberto I, Sapienza University, Rome, Italy
| | - Rosa Prato
- IRCCS Ospedale Policlinico San Martino Genova, and Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Vincenzo Restivo
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, Palermo, Italy
| | - Francesco Vitale
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, Palermo, Italy
| | | | - Stefano Merler
- Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy
| | | | - Paola Stefanelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | | |
Collapse
|
5
|
Curtis JR, Yun H, Chen L, Ford SS, van Hoogstraten H, Fiore S, Ford K, Praestgaard A, Rehberg M, Choy E. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry. Rheumatol Ther 2023; 10:1055-1072. [PMID: 37349636 PMCID: PMC10326227 DOI: 10.1007/s40744-023-00568-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Accepted: 05/30/2023] [Indexed: 06/24/2023] Open
Abstract
INTRODUCTION Clinical trial findings may not be generalizable to routine practice. This study evaluated sarilumab effectiveness in patients with rheumatoid arthritis (RA) and tested the real-world applicability of a response prediction rule, derived from trial data using machine learning (based on C-reactive protein [CRP] > 12.3 mg/l and seropositivity [anticyclic citrullinated peptide antibodies, ACPA +]). METHODS Sarilumab initiators from the ACR-RISE Registry, with ≥ 1 prescription on/after its FDA approval (2017-2020), were divided into three cohorts based on progressively restrictive criteria: Cohort A (had active disease), Cohort B (met eligibility criteria of a phase 3 trial in RA patients with inadequate response/intolerance to tumor necrosis factor inhibitors [TNFi]), and Cohort C (characteristics matched to the phase 3 trial baseline). Mean changes in Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) were evaluated at 6 and 12 months. In a separate cohort, predictive rule was tested based on CRP levels and seropositive status (ACPA and/or rheumatoid factor); patients were categorized into rule-positive (seropositive with CRP > 12.3 mg/l) and rule-negative groups to compare the odds of achieving CDAI low disease activity (LDA)/remission and minimal clinically important difference (MCID) over 24 weeks. RESULTS Among sarilumab initiators (N = 2949), treatment effectiveness was noted across cohorts, with greater improvement noted for Cohort C at 6 and 12 months. Among the predictive rule cohort (N = 205), rule-positive (vs. rule-negative) patients were more likely to reach LDA (odds ratio: 1.5 [0.7, 3.2]) and MCID (1.1 [0.5, 2.4]). Sensitivity analyses (CRP > 5 mg/l) showed better response to sarilumab in rule-positive patients. CONCLUSIONS In real-world setting, sarilumab demonstrated treatment effectiveness, with greater improvements in the most selective population, mirroring phase 3 TNFi-refractory and rule-positive RA patients. Seropositivity appeared a stronger driver for treatment response than CRP, although optimization of the rule in routine practice requires further data.
Collapse
Affiliation(s)
- Jeffrey R Curtis
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
| | - Huifeng Yun
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - Lang Chen
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | | | | | | | | | | | | | - Ernest Choy
- CREATE Centre, Cardiff University, Cardiff, UK
| |
Collapse
|
6
|
Curtis JR, Fiore S, Ford K, Janak JC, Chang H, Pappas DA, Blachley T, Emeanuru K, Bykerk VP. Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry. J Clin Rheumatol 2023; 29:e47-e51. [PMID: 37000177 DOI: 10.1097/rhu.0000000000001956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/01/2023]
Abstract
OBJECTIVE The aim of this study was to assess the change in disease activity associated with switching from 1 biologic/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) to another in patients with rheumatoid arthritis who did not achieve low disease activity (LDA) after 6 to 12 months of their initial treatment. METHODS This observational study included patients from the CorEvitas Rheumatoid Arthritis Registry, who initiated a b/tsDMARD at the index visit (prebaseline), had any clinical disease activity index (CDAI) improvement but did not achieve LDA/remission at the subsequent visit (baseline), and switched therapy at baseline or between baseline and follow-up visits. Regardless of the preswitch CDAI value, 2 thresholds of CDAI change were used to define meaningful improvement and worsening for all patients: ≥6 units and ≥12 units; no meaningful change was defined as any change between -6 to +6 units and -12 to +12 units, based on respective thresholds. RESULTS Of 1226 patients fulfilling the inclusion criteria, 93 (7.6%) switched therapy at baseline or between baseline and follow-up, after an inadequate response at the baseline visit. At follow-up, meaningful worsening occurred in 30.1% and 12.9% of switchers, whereas the remaining switchers achieved meaningful improvement (34.4% and 20.4%) or had no meaningful change (35.5% and 66.7%), based on the thresholds of ≥6 and ≥12 units, respectively. CONCLUSIONS Rheumatoid arthritis patients, who had not achieved LDA and switched b/tsDMARD, were more likely to have meaningful improvement or no change, rather than meaningful worsening. These data may help some patients overcome their hesitancy to switch therapy, potentially improving clinical outcomes.
Collapse
|
7
|
Torregrosa-Martin C, Ibarra A, Aguilar J, Ambi F, Arranz F, Arbeiter F, Bagnasco A, Becerril S, Bernardi D, Bolzon B, Botta E, Brenneis B, Cappelli M, Cara P, Castellanos J, Cosic D, De la Morena C, Diez A, Ericsson G, García A, García M, Garcinuño B, Gutiérrez J, Gutiérrez V, Jimenez-Rey D, Dezsi T, Ferreira MJ, Fiore S, Krolas W, Lorenzo R, Luque M, Maciá L, Marroncle J, Martin-Fuertes F, Marugán J, Maestre J, Meléndez C, Miccichè G, Mollá J, Moreno A, Nitti F, Núñez C, Ogando F, Pinna T, Oliver C, Podadera I, Prieto C, Prokopowicz R, Qiu Y, Rapisarda D, Regidor D, Rodríguez E, Sabogal A, Sánchez-Herranz D, Sanmarti M, Seguí L, Serikov A, Tadić T, Talarowska A, Wiacek U, Weber M, Valenzuela J, Zsakai A. Overview of IFMIF-DONES diagnostics: Requirements and techniques. Fusion Engineering and Design 2023. [DOI: 10.1016/j.fusengdes.2023.113556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
|
8
|
Shadick N, Hagino O, Praestgaard A, Fiore S, Weinblatt M, Burmester G. Association of hemoglobin levels with radiographic progression in patients with rheumatoid arthritis: an analysis from the BRASS registry. Arthritis Res Ther 2023; 25:88. [PMID: 37237405 DOI: 10.1186/s13075-023-03068-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 05/15/2023] [Indexed: 05/28/2023] Open
Abstract
BACKGROUND To evaluate baseline hemoglobin (Hb) and radiographic progression over time in patients enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) registry. METHODS The BRASS is a prospective observational registry of patients with rheumatoid arthritis. BRASS Hb data and total sharp score data were matched with the main BRASS patients. Hb at baseline was categorized per the World Health Organization guidelines. Mean Hb, mean total sharp score, and mean changes over time from baseline to month 120 were summarized (overall, by low/normal Hb, and by current medication at baseline). All analyses were descriptive. RESULTS Out of the total (N = 1114) rheumatoid arthritis patients included in the analysis, patients with low Hb at baseline (n = 224 [20%]) had longer disease duration and higher disease activity and reported more pain compared with patients with normal Hb at baseline (n = 890 [80%]). Patients with low Hb at baseline continued to have lower Hb than patients with normal Hb throughout 10 years; although, on average, patients in the low Hb subgroup exhibited a steady increase in Hb levels. A larger increase in total sharp score over time was observed for patients with low Hb than for patients with normal Hb. No meaningful differences potentially attributable to medication at baseline were detected. CONCLUSIONS Patients with low Hb levels at baseline tended to have increased radiographic progression as measured by total sharp score compared with patients with rheumatoid arthritis having normal Hb levels. Patients with low Hb experienced sustained improvements in Hb levels over time, regardless of the class of medication used. TRIAL REGISTRATION ClinicalTrials.gov NCT01793103.
Collapse
Affiliation(s)
- Nancy Shadick
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
| | - Owen Hagino
- Sanofi, Research and Development, Bridgewater, NJ, USA
| | | | - Stefano Fiore
- Global Medical Affairs, Biostatistics, Cambridge, MA, USA
| | - Michael Weinblatt
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA
| | - Gerd Burmester
- Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany
| |
Collapse
|
9
|
Sebba A, Bingham CO, Bykerk VP, Fiore S, Ford K, Janak JC, Pappas DA, Blachley T, Dave SS, Kremer JM, Yu M, Choy E. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Clin Rheumatol 2023:10.1007/s10067-023-06588-7. [PMID: 37060528 DOI: 10.1007/s10067-023-06588-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 02/22/2023] [Accepted: 03/24/2023] [Indexed: 04/16/2023]
Abstract
OBJECTIVE Randomized controlled trials (RCTs) in biologic-naïve rheumatoid arthritis (RA) patients with high disease activity and inadequate response/intolerance to methotrexate have shown interleukin-6 (IL-6) receptor inhibitors (IL-6Ri) to be superior to tumor necrosis factor inhibitors (TNFi) as monotherapy. This observational study aimed to compare the effectiveness of TNFi vs IL-6Ri as mono- or combination therapy in biologic/targeted synthetic (b/ts) -experienced RA patients with moderate/high disease activity. METHODS Eligible b/ts-experienced patients from the CorEvitas RA registry were categorized as TNFi and IL-6Ri initiators, with subgroups initiating as mono- or combination therapy. Mixed-effects regression models evaluated the impact of treatment on Clinical Disease Activity Index (CDAI), patient-reported outcomes, and disproportionate pain (DP). Unadjusted and covariate-adjusted effects were reported. RESULTS Patients initiating IL-6Ri (n = 286) vs TNFi monotherapy (n = 737) were older, had a longer RA history and higher baseline CDAI, and were more likely to initiate as third-line therapy; IL-6Ri (n = 401) vs TNFi (n = 1315) combination therapy initiators had higher baseline CDAI and were more likely to initiate as third-line therapy. No significant differences were noted in the outcomes between TNFi and IL-6Ri initiators (as mono- or combination therapy). CONCLUSION This observational study showed no significant differences in outcomes among b/ts-experienced TNFi vs IL-6Ri initiators, as either mono- or combination therapy. These findings were in contrast with the previous RCTs in biologic-naïve patients and could be explained by the differences in the patient characteristics included in this study. Further studies are needed to help understand the reasons for this discrepancy in the real-world b/ts-experienced population.
Collapse
Affiliation(s)
- Anthony Sebba
- Rheumatology, Arthritis Associates, Palm Harbor, FL, USA.
| | - Clifton O Bingham
- Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA
| | - Vivian P Bykerk
- Inflammatory Arthritis Center, Hospital for Special Surgery, New York, NY, USA
| | | | - Kerri Ford
- Medical Affairs, Sanofi, Cambridge, MA, USA
| | | | - Dimitrios A Pappas
- CorEvitas, LLC, Waltham, MA, USA
- Division of Rheumatology, Columbia University, New York, NY, USA
| | | | | | - Joel M Kremer
- CorEvitas, LLC, Waltham, MA, USA
- Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, NY, USA
| | - Miao Yu
- CorEvitas, LLC, Waltham, MA, USA
| | - Ernest Choy
- CREATE Centre, Division of Infection and Immunity, Cardiff University, Wales, UK
| |
Collapse
|
10
|
Ricci D, Etna MP, Severa M, Fiore S, Rizzo F, Iannetta M, Andreoni M, Balducci S, Stefanelli P, Palamara AT, Coccia EM. Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model. Int Immunopharmacol 2023; 117:109996. [PMID: 36933449 PMCID: PMC10008813 DOI: 10.1016/j.intimp.2023.109996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Revised: 02/27/2023] [Accepted: 02/28/2023] [Indexed: 03/16/2023]
Abstract
The peculiar property of Thymosin alpha 1 (Tα1) to act as master regulator of immune homeostasis has been successfully defined in different physiological and pathological contexts ranging from cancer to infection. Interestingly, recent papers also demonstrated its mitigating effect on the "cytokine storm" as well as on the T-cell exhaustion/activation in SARS-CoV-2 infected individuals. Nevertheless, in spite of the increasing knowledge on Tα1-induced effects on T cell response confirming the distinctive features of this multifaceted peptide, little is known on its effects on innate immunity during SARS-CoV-2 infection. Here, we interrogated peripheral blood mononuclear cell (PBMC) cultures stimulated with SARS-CoV-2 to disclose Tα1 properties on the main cell players of early response to infection, namely monocytes and myeloid dendritic cells (mDC). Moving from ex vivo data showing an enhancement in the frequency of inflammatory monocytes and activated mDC in COVID-19 patients, a PBMC-based experimental setting reproduced in vitro a similar profile with an increased percentage of CD16+ inflammatory monocytes and mDC expressing CD86 and HLA-DR activation markers in response to SARS-CoV-2 stimulation. Interestingly, the treatment of SARS-CoV-2-stimulated PBMC with Tα1 dampened the inflammatory/activation status of both monocytes and mDC by reducing the release of pro-inflammatory mediators, including TNF-α, IL-6 and IL-8, while promoting the production of the anti-inflammatory cytokine IL-10. This study further clarifies the working hypothesis on Tα1 mitigating action on COVID-19 inflammatory condition. Moreover, these evidence shed light on inflammatory pathways and cell types involved in acute SARS-CoV-2 infection and likely targetable by newly immune-regulating therapeutic approaches.
Collapse
Affiliation(s)
- Daniela Ricci
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; Roma Tre University, Rome, Italy
| | - Marilena Paola Etna
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Martina Severa
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Fabiana Rizzo
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Marco Iannetta
- Department of System Medicine, Infectious Disease Unit, University of Rome Tor Vergata, Rome, Italy
| | - Massimo Andreoni
- Department of System Medicine, Infectious Disease Unit, University of Rome Tor Vergata, Rome, Italy
| | | | - Paola Stefanelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | | | | |
Collapse
|
11
|
Cinicola BL, Piano Mortari E, Zicari AM, Agrati C, Bordoni V, Albano C, Fedele G, Schiavoni I, Leone P, Fiore S, Capponi M, Conti MG, Petrarca L, Stefanelli P, Spalice A, Midulla F, Palamara AT, Quinti I, Locatelli F, Carsetti R. The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age. Front Immunol 2022; 13:1094727. [PMID: 36591287 PMCID: PMC9797965 DOI: 10.3389/fimmu.2022.1094727] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 11/29/2022] [Indexed: 12/23/2022] Open
Abstract
SARS-CoV-2 mRNA vaccines prevent severe COVID-19 by generating immune memory, comprising specific antibodies and memory B and T cells. Although children are at low risk of severe COVID-19, the spreading of highly transmissible variants has led to increasing in COVID-19 cases and hospitalizations also in the youngest, but vaccine coverage remains low. Immunogenicity to mRNA vaccines has not been extensively studied in children 5 to 11 years old. In particular, cellular immunity to the wild-type strain (Wuhan) and the cross-reactive response to the Omicron variant of concern has not been investigated. We assessed the humoral and cellular immune response to the SARS-CoV-2 BNT162b2 vaccine in 27 healthy children. We demonstrated that vaccination induced a potent humoral and cellular immune response in all vaccinees. By using spike-specific memory B cells as a measurable imprint of a previous infection, we found that 50% of the children had signs of a past, undiagnosed infection before vaccination. Children with pre-existent immune memory generated significantly increased levels of specific antibodies, and memory T and B cells, directed against not only the wild type virus but also the omicron variant.
Collapse
Affiliation(s)
- Bianca Laura Cinicola
- Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy,Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
| | - E Piano Mortari
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy,B cell unit, Immunology Research Area, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
| | - Anna Maria Zicari
- Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy
| | - Chiara Agrati
- Department of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
| | - Veronica Bordoni
- Department of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
| | - Christian Albano
- B cell unit, Immunology Research Area, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
| | - Giorgio Fedele
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Ilaria Schiavoni
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Pasqualina Leone
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Martina Capponi
- Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy
| | - Maria Giulia Conti
- Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy
| | - Laura Petrarca
- Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy
| | - Paola Stefanelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Alberto Spalice
- Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy
| | - Fabio Midulla
- Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy
| | | | - Isabella Quinti
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
| | - Franco Locatelli
- Department of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy,Catholic University of the Sacred Hearth, Rome, Italy
| | - Rita Carsetti
- B cell unit, Immunology Research Area, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy,*Correspondence: Rita Carsetti,
| |
Collapse
|
12
|
Fedele G, Trentini F, Schiavoni I, Abrignani S, Antonelli G, Baldo V, Baldovin T, Bandera A, Bonura F, Clerici P, De Paschale M, Fortunato F, Gori A, Grifantini R, Icardi G, Lazzarotto T, Lodi V, Mastroianni CM, Orsi A, Prato R, Restivo V, Carsetti R, Piano Mortari E, Leone P, Olivetta E, Fiore S, Di Martino A, Brusaferro S, Merler S, Palamara AT, Stefanelli P. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. Front Immunol 2022; 13:1021396. [PMID: 36389704 PMCID: PMC9661524 DOI: 10.3389/fimmu.2022.1021396] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 09/26/2022] [Indexed: 11/26/2023] Open
Abstract
To date there has been limited head-to-head evaluation of immune responses to different types of COVID-19 vaccines. A real-world population-based longitudinal study was designed with the aim to define the magnitude and duration of immunity induced by each of four different COVID-19 vaccines available in Italy at the time of this study. Overall, 2497 individuals were enrolled at time of their first vaccination (T0). Vaccine-specific antibody responses induced over time by Comirnaty, Spikevax, Vaxzevria, Janssen Ad26.COV2.S and heterologous vaccination were compared up to six months after immunization. On a subset of Comirnaty vaccinees, serology data were correlated with the ability to neutralize a reference SARS-CoV-2 B strain, as well as Delta AY.4 and Omicron BA.1. The frequency of SARS-CoV-2-specific CD4+ T cells, CD8+ T cells, and memory B cells induced by the four different vaccines was assessed six months after the immunization. We found that mRNA vaccines are stronger inducer of anti-Spike IgG and B-memory cell responses. Humoral immune responses are lower in frail elderly subjects. Neutralization of the Delta AY.4 and Omicron BA.1 variants is severely impaired, especially in older individuals. Most vaccinees display a vaccine-specific T-cell memory six months after the vaccination. By describing the immunological response during the first phase of COVID-19 vaccination campaign in different cohorts and considering several aspects of the immunological response, this study allowed to collect key information that could facilitate the implementation of effective prevention and control measures against SARS-CoV-2.
Collapse
Affiliation(s)
- Giorgio Fedele
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Filippo Trentini
- Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy
- Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy
| | - Ilaria Schiavoni
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Sergio Abrignani
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- Department of Clinical Sciences & Community Health, University of Milan, Milan, Italy
| | - Guido Antonelli
- Department of Molecular Medicine, AOU Policlinico Umberto I, Sapienza University, Rome, Italy
| | - Vincenzo Baldo
- Laboratory of Hygiene and Applied Microbiology, Hygiene and Public Health Unit, Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Tatjana Baldovin
- Laboratory of Hygiene and Applied Microbiology, Hygiene and Public Health Unit, Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Alessandra Bandera
- Infectious Diseases Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan, Italy
| | - Filippa Bonura
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy
| | - Pierangelo Clerici
- Microbiology Unit, Azienda Socio Sanitaria Territoriale (ASST) Ovest Milanese, Milan, Italy
| | - Massimo De Paschale
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Francesca Fortunato
- Hygiene Unit, Policlinico Riuniti Foggia Hospital, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
| | - Andrea Gori
- Infectious Diseases Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan, Italy
| | - Renata Grifantini
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
| | - Giancarlo Icardi
- Hygiene Unit, IRCCS Ospedale Policlinico San Martino Genova, and Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Tiziana Lazzarotto
- Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - Vittorio Lodi
- Occupational Health Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Claudio Maria Mastroianni
- Department of Public Health and Infectious Disease, AOU Policlinico Umberto I, Sapienza University, Rome, Italy
| | - Andrea Orsi
- Hygiene Unit, IRCCS Ospedale Policlinico San Martino Genova, and Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Rosa Prato
- Hygiene Unit, Policlinico Riuniti Foggia Hospital, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
| | - Vincenzo Restivo
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy
| | - Rita Carsetti
- B Cell Lab, Immunology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
| | - Eva Piano Mortari
- B Cell Lab, Immunology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
| | - Pasqualina Leone
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Eleonora Olivetta
- National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Angela Di Martino
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | | | - Stefano Merler
- Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy
| | | | - Paola Stefanelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| |
Collapse
|
13
|
Rubbert-Roth A, Furst DE, Fiore S, Praestgaard A, Bykerk V, Bingham CO, Charles-Schoeman C, Burmester G. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. Arthritis Res Ther 2022; 24:207. [PMID: 36008838 PMCID: PMC9404615 DOI: 10.1186/s13075-022-02891-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Accepted: 08/07/2022] [Indexed: 11/29/2022] Open
Abstract
Background Anemia is common in patients with rheumatoid arthritis (RA). Higher hemoglobin (Hb) levels may be associated with better clinical outcomes and patient-reported outcomes (PROs). To assess this hypothesis, we conducted two post hoc analyses in three sarilumab phase III studies: TARGET, MOBILITY, and MONARCH. Methods Pooled data from combination therapy from placebo-controlled MOBILITY (sarilumab + methotrexate) and TARGET (sarilumab + conventional synthetic disease-modifying antirheumatic drugs [csDMARDs]) and monotherapy data from active-controlled MONARCH (sarilumab vs. adalimumab) studies were included. Associations between Hb levels and clinical measures and PROs were assessed over 24 weeks. The mean changes from baseline in clinical outcomes and PROs (to week 24) and radiographic outcomes (to week 52) were evaluated between low and normal Hb levels (based on the World Health Organization [WHO] criteria). Results From TARGET, MOBILITY, and MONARCH, 546, 1197, and 369 patients, respectively, were stratified according to Hb levels (low vs. normal). Over 24 weeks, higher Hb levels were found to be consistently associated with better clinical outcomes and PROs in combination therapy and monotherapy groups and were more pronounced among the patients treated with sarilumab than those treated with placebo and adalimumab. The mean change from baseline to week 24 in clinical efficacy measures and PROs was similar in patients with low vs. normal Hb at baseline. Differences between sarilumab and/or adalimumab, for all outcomes, were larger for low Hb subgroups. In MOBILITY, by week 52, the inhibition of progression of structural damage (assessed via Modified Total Sharp Score [mTSS]) was 84% (sarilumab 200 mg) and 68% (sarilumab 150 mg) vs. placebo in patients with low Hb and 97% (sarilumab 200 mg) and 68% (sarilumab 150 mg) vs. placebo in patients with normal Hb. Similar results were observed for other radiographic outcomes. Conclusions In these post hoc analyses, a consistent relationship was observed between higher Hb levels and better clinical outcomes and PROs in patients with RA. Irrespective of the baseline Hb levels, sarilumab treatment was associated with improvements in clinical measures and PROs over 24 weeks (improvements were more pronounced than those with adalimumab treatment) and mitigation of joint damage progression over 52 weeks. Trial registration ClinTrials.gov NCT01061736, NCT01709578, and NCT02332590 Supplementary Information The online version contains supplementary material available at 10.1186/s13075-022-02891-x.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Gerd Burmester
- Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany
| |
Collapse
|
14
|
Cerasuolo PG, Gambini G, De Lorenzis E, Fiore S, Verardi L, Natalello G, Alonzi G, Rizzo S, D’agostino MA, Bosello SL. POS0887 CHORIORETINAL MICROVASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe optical coherence tomography angiography (OCTA) is a new non-invasive imaging technique that can detect flow and provide information about the vessel density (VD) at different layers in the eye. The ocular microvascular network has been only occasionally addressed as disease target in scleroderma (SSc) considering the relatively low prevalence of ocular symptoms in these patients.ObjectivesThe study aims to evaluate retinal and choriocapillaris microvasculature in a group of SSc patients compared to matched controls (HC)and according to disease characteristics, capillaroscopy findings and pulmonary function tests.MethodsVD was assessed through OCTA at the retinal superficial (SCP) and deep (DCP) capillary plexus, at the foveal avascular zone perimeter (FAZP) and at the choriocapillaris (CC) of 30 SSc patients compared to 30 sex- and age-matched subjects without any retinal disease.ResultsThe SSc patients (age 57.3±10.0, female 86.7%) had diffuse cutaneous skin disease in 30.0% of the cases, an average disease duration of 10.4±7.2 yy, and anti-centromere and anti-Scl70 antibody positivity in 40.0%and in 30.0% of the cases, respectively. Compared to the HC, SSc showed an impaired VD at SCP (47.7±3.6 vs59.1±3.5%, p=0.009), DCP (50.0±6.7 vs 54.3±6.4%, p=0.015), FAZP (48.7±4.55 vs 51.0±3.55%, p=0.034) and CC(67.1±2.2 vs 68.6±1.7, p=.005). Moreover, in the SSc group, the presence of digital ulcers (46.7%),telangiectasias (43.3%) and interstitial lung disease (46.7%) was related to reduced VD at FAZP (46.8±4.1 vs50.3±4.3%, p=0.033), CC (66.1±1.4 vs 67.9±2.4%, p=0.004), and DCP (47.2±8.8 vs 51.9±4.3, p=0.004),respectively. Lastly, the average capillary density on capillaroscopy showed a positive correlation with VD at FAZP (r=0.474, p=0.008), DCP (r=0.414, p=0.023), and foveal CC (r=0.482, p=0.007) and there was also a correlation between CC and both DLco (r=0.467, p=0.009) and FVC/DLco (r=-0.436, p=0.004).ConclusionThe SSc patients in our cohort showed lower ocular vessel density at different levels compared to HC. Furthermore, impaired VD at different levels of the eye correlates with the organ involvement and the degree of digital and pulmonary microvascular impairment. According to those data, the OCTA could be proposed as a biomarker tool to investigate the microvascular abnormalities in SSc.Disclosure of InterestsNone declared
Collapse
|
15
|
Padula AS, Pappas DA, Fiore S, Blachley TS, Ford K, Emeanuru K, Kremer JM. The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. Arthritis Res Ther 2022; 24:276. [PMID: 36544236 PMCID: PMC9769058 DOI: 10.1186/s13075-022-02955-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 11/13/2022] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND To evaluate the effects of tumor necrosis factor inhibitors (TNFi), interleukin-6 receptor inhibitors (IL-6Ri), and Janus kinase inhibitors (JAKi) on hemoglobin (Hb) and C-reactive protein (CRP) levels in adults enrolled in CorEvitas (formerly Corrona), a large US rheumatoid arthritis (RA) registry. METHODS Patients who initiated TNFi, IL-6Ri, or JAKi treatment during or after January 2010, had Hb and CRP measurements at baseline and 6-month follow-up (± 3 months) and had continued therapy at least until that follow-up, through March 2020, were included in the analysis. Changes in Hb and CRP were assessed at month 6. Abnormal Hb was defined as < 12 g/dL (women) or < 13 g/dL (men); abnormal CRP was ≥ 0.8 mg/dL. Differences in Hb and CRP levels were evaluated using multivariable regression. RESULTS Of 2772 patients (TNFi, 65%; IL-6Ri, 17%; JAKi, 17%) evaluated, 1044 (38%) had abnormal Hb or CRP at initiation; an additional 252 (9%) had both abnormal Hb and CRP. At month 6, the IL-6Ri group had a greater Hb increase than the TNFi (mean difference in effect on Hb: 0.28 g/dL; 95% CI 0.19-0.38) and JAKi (mean difference in effect on Hb: 0.47 g/dL; 95% CI 0.35-0.58) groups, regardless of baseline Hb status (both p < 0.001). The CRP decrease at month 6 was greater with IL-6Ri compared with TNFi and JAKi, regardless of baseline CRP status (both p < 0.05). CONCLUSION These real-world results align with the mechanism of IL-6R inhibition and may inform treatment decisions for patients with RA.
Collapse
Affiliation(s)
- Anthony S. Padula
- Northern California Arthritis Center, 120 La Casa Via, Suite 204, Walnut Creek, CA 94598 USA
| | | | - Stefano Fiore
- grid.417555.70000 0000 8814 392XSanofi, Bridgewater, NJ USA
| | | | - Kerri Ford
- grid.417555.70000 0000 8814 392XSanofi, Bridgewater, NJ USA
| | - Kelechi Emeanuru
- CorEvitas, Waltham, MA USA ,grid.423257.50000 0004 0510 2209Evidera, Bethesda, MD USA
| | | |
Collapse
|
16
|
Fontana S, Buttinelli G, Fiore S, Amato C, Pataracchia M, Kota M, Aćimović J, Blažević M, Mulaomerović M, Nikolaeva-Glomb L, Mentis A, Voulgari-Kokota A, Gashi L, Kaçaniku-Gunga P, Barbara C, Melillo J, Protic J, Filipović-Vignjevic S, O’Connor PM, D’Alberto A, Orioli R, Siddu A, Saxentoff E, Stefanelli P. Retrospective Analysis of Six Years of Acute Flaccid Paralysis Surveillance and Polio Vaccine Coverage Reported by Italy, Serbia, Bosnia and Herzegovina, Montenegro, Bulgaria, Kosovo, Albania, North Macedonia, Malta, and Greece. Vaccines (Basel) 2021; 10:vaccines10010044. [PMID: 35062705 PMCID: PMC8779529 DOI: 10.3390/vaccines10010044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 12/23/2021] [Accepted: 12/24/2021] [Indexed: 11/16/2022] Open
Abstract
Here we analyzed six years of acute flaccid paralysis (AFP) surveillance, from 2015 to 2020, of 10 countries linked to the WHO Regional Reference Laboratory, at the Istituto Superiore di Sanità, Italy. The analysis also comprises the polio vaccine coverage available (2015–2019) and enterovirus (EV) identification and typing data. Centralized Information System for Infectious Diseases and Laboratory Data Management System databases were used to obtain data on AFP indicators and laboratory performance and countries’ vaccine coverage from 2015 to 2019. EV isolation, identification, and typing were performed by each country according to WHO protocols. Overall, a general AFP underreporting was observed. Non-Polio Enterovirus (NPEV) typing showed a high heterogeneity: over the years, several genotypes of coxsackievirus and echovirus have been identified. The polio vaccine coverage, for the data available, differs among countries. This evaluation allows for the collection, for the first time, of data from the countries of the Balkan area regarding AFP surveillance and polio vaccine coverage. The need, for some countries, to enhance the surveillance systems and to promote the polio vaccine uptake, in order to maintain the polio-free status, is evident.
Collapse
Affiliation(s)
- Stefano Fontana
- Department of Infectious Disease, Istituto Superiore di Sanità, 00161 Rome, Italy; (S.F.); (G.B.); (S.F.); (C.A.); (M.P.)
| | - Gabriele Buttinelli
- Department of Infectious Disease, Istituto Superiore di Sanità, 00161 Rome, Italy; (S.F.); (G.B.); (S.F.); (C.A.); (M.P.)
| | - Stefano Fiore
- Department of Infectious Disease, Istituto Superiore di Sanità, 00161 Rome, Italy; (S.F.); (G.B.); (S.F.); (C.A.); (M.P.)
| | - Concetta Amato
- Department of Infectious Disease, Istituto Superiore di Sanità, 00161 Rome, Italy; (S.F.); (G.B.); (S.F.); (C.A.); (M.P.)
| | - Marco Pataracchia
- Department of Infectious Disease, Istituto Superiore di Sanità, 00161 Rome, Italy; (S.F.); (G.B.); (S.F.); (C.A.); (M.P.)
| | - Majlinda Kota
- Laboratory of Virology, Department of Control of Infectious Diseases, Institute of Public Health, 1001 Tirana, Albania;
| | - Jela Aćimović
- Department of Epidemiology, Public Health Institute of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina;
| | - Mia Blažević
- Institute for Public Health of Federation Bosnia and Herzegovina, 71000 Sarajevo, Bosnia and Herzegovina; (M.B.); (M.M.)
| | - Mirsada Mulaomerović
- Institute for Public Health of Federation Bosnia and Herzegovina, 71000 Sarajevo, Bosnia and Herzegovina; (M.B.); (M.M.)
| | - Lubomira Nikolaeva-Glomb
- Department of Virology, National Centre of Infectious and Parasitic Diseases, 1504 Sofia, Bulgaria;
| | - Andreas Mentis
- National Poliovirus/Enterovirus Reference Laboratory, Diagnostic Department, Hellenic Pasteur Institute, 11521 Athens, Greece; (A.M.); (A.V.-K.)
| | - Androniki Voulgari-Kokota
- National Poliovirus/Enterovirus Reference Laboratory, Diagnostic Department, Hellenic Pasteur Institute, 11521 Athens, Greece; (A.M.); (A.V.-K.)
| | - Luljeta Gashi
- Department of Epidemiology, National Institute of Public Health, 10000 Pristina, Kosovo; (L.G.); (P.K.-G.)
| | - Pranvera Kaçaniku-Gunga
- Department of Epidemiology, National Institute of Public Health, 10000 Pristina, Kosovo; (L.G.); (P.K.-G.)
| | | | - Jackie Melillo
- Department for Health Regulation, Health Promotion and Disease Prevention, MSD2090 Msida, Malta;
| | - Jelena Protic
- National Reference Laboratory for ARBO Viruses and Hemorrhagic Fever, Institute of Virology, Vaccines and Sera “Torlak”, 11152 Belgrade, Serbia;
| | - Svetlana Filipović-Vignjevic
- Diagnostics and Research and Development, Institute of Virology, Vaccines and Sera “Torlak”, 11152 Belgrade, Serbia;
| | - Patrick M. O’Connor
- Global Immunization Division US Centers for Disease Control and Prevention, Atlanta, GA 30333, USA;
| | - Alessandra D’Alberto
- Prevention of Communicable Diseases and International Prophylaxis, Directorate General of Health Prevention, Ministry of Health, 00144 Rome, Italy; (A.D.); (R.O.); (A.S.)
| | - Riccardo Orioli
- Prevention of Communicable Diseases and International Prophylaxis, Directorate General of Health Prevention, Ministry of Health, 00144 Rome, Italy; (A.D.); (R.O.); (A.S.)
| | - Andrea Siddu
- Prevention of Communicable Diseases and International Prophylaxis, Directorate General of Health Prevention, Ministry of Health, 00144 Rome, Italy; (A.D.); (R.O.); (A.S.)
| | - Eugene Saxentoff
- Division of Health Emergencies and Communicable Diseases (DEC), Regional Office for Europe World Health Organization, DK-2100 Copenhagen, Denmark;
| | - Paola Stefanelli
- Department of Infectious Disease, Istituto Superiore di Sanità, 00161 Rome, Italy; (S.F.); (G.B.); (S.F.); (C.A.); (M.P.)
- Correspondence: ; Tel.: +39-06-4990-2126
| |
Collapse
|
17
|
Abudinén F, Adachi I, Adamczyk K, Ahlburg P, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Baur A, Babu V, Baehr S, Bambade P, Banerjee S, Bansal S, Baudot J, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertemes M, Bertholet E, Bessner M, Bettarini S, Bianchi F, Bilka T, Biswas D, Bozek A, Bračko M, Branchini P, Braun N, Browder TE, Budano A, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Červenkov D, Chang P, Cheaib R, Chekelian V, Chen C, Chen YT, Cheon BG, Chilikin K, Chirapatpimol K, Cho K, Cho SJ, Choudhury S, Cinabro D, Corona L, Cremaldi LM, Cunliffe S, Czank T, Dattola F, De La Cruz-Burelo E, de Marino G, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Di Canto A, Di Capua F, Dingfelder J, Doležal Z, Domínguez Jiménez I, Dong TV, Dort K, Dubey S, Duell S, Dujany G, Eidelman S, Eliachevitch M, Epifanov D, Ferber T, Ferlewicz D, Fillinger T, Finocchiaro G, Fiore S, Fodor A, Forti F, Frey A, Fulsom BG, Gabyshev N, Ganiev E, Garcia-Hernandez M, Garmash A, Gaur V, Gaz A, Gellrich A, Giordano R, Giri A, Glazov A, Gobbo B, Godang R, Goldenzweig P, Golob B, Grace P, Gradl W, Graziani E, Greenwald D, Guan Y, Gudkova K, Hadjivasiliou C, Halder S, Hara K, Hartbrich O, Hayasaka K, Hayashii H, Hazra S, Hearty C, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hirata H, Hoek M, Hohmann M, Hsu CL, Humair T, Iijima T, Inami K, Inguglia G, Irakkathil Jabbar J, Ishikawa A, Itoh R, Iwasaki M, Iwasaki Y, Jackson P, Jacobs WW, Jaffe DE, Jin Y, Joo C, Junkerkalefeld H, Kaliyar AB, Kandra J, Kang KH, Karl R, Karyan G, Kawasaki T, Ketter C, Kichimi H, Kiesling C, Kim CH, Kim DY, Kim YK, Kimmel TD, Kodyš P, Koga T, Kohani S, Konno T, Korobov A, Korpar S, Kovalenko E, Kraetzschmar TMG, Krinner F, Križan P, Krokovny P, Kuhr T, Kumar J, Kumar M, Kumar R, Kumara K, Kunigo T, Kurz S, Kuzmin A, Kwon YJ, Lacaprara S, Lai YT, La Licata C, Lanceri L, Lange JS, Laurenza M, Lautenbach K, Le Diberder FR, Lee SC, Leitl P, Levit D, Lewis PM, Li C, Li LK, Li SX, Li YB, Libby J, Lieret K, Liptak Z, Liu QY, Liventsev D, Longo S, Lozar A, Lueck T, Lyu C, Maggiora M, Maity S, Manfredi R, Manoni E, Marcello S, Marinas C, Martini A, Masuda M, Matsuda T, Matsuoka K, Matvienko D, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Miyake H, Mizuk R, Mohanty GB, Moser HG, Mrvar M, Müller FJ, Murphy C, Mussa R, Nakamura KR, Nakao M, Natkaniec Z, Natochii A, Nayak M, Nazaryan G, Niebuhr C, Nisar NK, Nishida S, Nishimura K, Ogawa S, Onishchuk Y, Ono H, Onuki Y, Oskin P, Ozaki H, Pakhlov P, Pakhlova G, Paladino A, Pang T, Panta A, Paoloni E, Pardi S, Park H, Park SH, Paschen B, Passeri A, Pathak A, Patra S, Paul S, Pedlar TK, Peruzzi I, Pestotnik R, Piccolo M, Piilonen LE, Podesta-Lerma PLM, Podobnik T, Pokharel S, Polat G, Popov V, Praz C, Prell S, Prencipe E, Prim MT, Rad N, Rados P, Raiz S, Remnev M, Ripp-Baudot I, Ritter M, Rizzo G, Rizzuto LB, Robertson SH, Rodríguez Pérez D, Roney JM, Rostomyan A, Rout N, Russo G, Sahoo D, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schueler J, Schwanda C, Schwartz AJ, Seddon RM, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shiu JG, Shwartz B, Sibidanov A, Simon F, Sobie RJ, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Sumihama M, Sumisawa K, Summers DJ, Sutcliffe W, Suzuki SY, Svidras H, Tabata M, Takahashi M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Tanigawa H, Taniguchi N, Taras P, Tenchini F, Tonelli D, Torassa E, Toutounji N, Trabelsi K, Uchida M, Unno Y, Uno K, Uno S, Urquijo P, Ushiroda Y, Usov YV, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Wach B, Waheed E, Wakeling HM, Wan Abdullah W, Wang MZ, Wang XL, Warburton A, Watanuki S, Webb J, Welsch M, Wessel C, Wiechczynski J, Windel H, Xu XP, Yabsley BD, Yamada S, Yan W, Yang SB, Ye H, Yelton J, Yin JH, Yook YM, Yoshihara K, Yuan CZ, Yusa Y, Zani L, Zhilich V, Zhou QD, Zhou XY, Zhukova VI. Search for B^{+}→K^{+}νν[over ¯] Decays Using an Inclusive Tagging Method at Belle II. Phys Rev Lett 2021; 127:181802. [PMID: 34767404 DOI: 10.1103/physrevlett.127.181802] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 07/23/2021] [Accepted: 09/10/2021] [Indexed: 06/13/2023]
Abstract
A search for the flavor-changing neutral-current decay B^{+}→K^{+}νν[over ¯] is performed at the Belle II experiment at the SuperKEKB asymmetric energy electron-positron collider. The data sample corresponds to an integrated luminosity of 63 fb^{-1} collected at the ϒ(4S) resonance and a sample of 9 fb^{-1} collected at an energy 60 MeV below the resonance. Because the measurable decay signature involves only a single charged kaon, a novel measurement approach is used that exploits not only the properties of the B^{+}→K^{+}νν[over ¯] decay, but also the inclusive properties of the other B meson in the ϒ(4S)→BB[over ¯] event, to suppress the background from other B meson decays and light-quark pair production. This inclusive tagging approach offers a higher signal efficiency compared to previous searches. No significant signal is observed. An upper limit on the branching fraction of B^{+}→K^{+}νν[over ¯] of 4.1×10^{-5} is set at the 90% confidence level.
Collapse
Affiliation(s)
- F Abudinén
- INFN Sezione di Trieste, I-34127 Trieste
| | - I Adachi
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - K Adamczyk
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342
| | | | - H Aihara
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - N Akopov
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - A Aloisio
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - N Anh Ky
- Institute of Theoretical and Applied Research (ITAR), Duy Tan University, Hanoi 100000
- Institute of Physics, Vietnam Academy of Science and Technology (VAST), Hanoi
| | - D M Asner
- Brookhaven National Laboratory, Upton, New York 11973
| | - H Atmacan
- University of Cincinnati, Cincinnati, Ohio 45221
| | - T Aushev
- National Research University Higher School of Economics, Moscow 101000
| | - V Aushev
- Taras Shevchenko National University of Kiev, Kiev
| | - A Baur
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - V Babu
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Baehr
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - P Bambade
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292
| | - S Bansal
- Panjab University, Chandigarh 160014
| | - J Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - J Becker
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - P K Behera
- Indian Institute of Technology Madras, Chennai 600036
| | - J V Bennett
- University of Mississippi, University, Mississippi 38677
| | | | | | - M Bertemes
- Institute of High Energy Physics, Vienna 1050
| | - E Bertholet
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, 69978
| | - M Bessner
- University of Hawaii, Honolulu, Hawaii 96822
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - T Bilka
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - D Biswas
- University of Louisville, Louisville, Kentucky 40292
| | - A Bozek
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342
| | - M Bračko
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Chemistry and Chemical Engineering, University of Maribor, 2000 Maribor
| | | | - N Braun
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - T E Browder
- University of Hawaii, Honolulu, Hawaii 96822
| | - A Budano
- INFN Sezione di Roma Tre, I-00146 Roma
| | - S Bussino
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - M Campajola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - L Cao
- University of Bonn, 53115 Bonn
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - C Cecchi
- INFN Sezione di Perugia, I-06123 Perugia
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia
| | - D Červenkov
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - P Chang
- Department of Physics, National Taiwan University, Taipei 10617
| | - R Cheaib
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - V Chekelian
- Max-Planck-Institut für Physik, 80805 München
| | - C Chen
- Iowa State University, Ames, Iowa 50011
| | - Y-T Chen
- Department of Physics, National Taiwan University, Taipei 10617
| | - B G Cheon
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - K Chilikin
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | | | - K Cho
- Korea Institute of Science and Technology Information, Daejeon 34141
| | - S-J Cho
- Yonsei University, Seoul 03722
| | - S Choudhury
- Indian Institute of Technology Hyderabad, Telangana 502285
| | - D Cinabro
- Wayne State University, Detroit, Michigan 48202
| | - L Corona
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - L M Cremaldi
- University of Mississippi, University, Mississippi 38677
| | - S Cunliffe
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - T Czank
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - F Dattola
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - E De La Cruz-Burelo
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - G de Marino
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - G De Nardo
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - M De Nuccio
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - M Destefanis
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - S Dey
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, 69978
| | - A De Yta-Hernandez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - A Di Canto
- Brookhaven National Laboratory, Upton, New York 11973
| | - F Di Capua
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | | | - Z Doležal
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | | | - T V Dong
- Institute of Theoretical and Applied Research (ITAR), Duy Tan University, Hanoi 100000
| | - K Dort
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - S Dubey
- University of Hawaii, Honolulu, Hawaii 96822
| | - S Duell
- University of Bonn, 53115 Bonn
| | - G Dujany
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - S Eidelman
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | | | - D Epifanov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - T Ferber
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - D Ferlewicz
- School of Physics, University of Melbourne, Victoria 3010
| | - T Fillinger
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - G Finocchiaro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - S Fiore
- INFN Sezione di Roma, I-00185 Roma
| | - A Fodor
- McGill University, Montréal, Québec, H3A 2T8
| | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - A Frey
- II. Physikalisches Institut, Georg-August-Universität Göttingen, 37073 Göttingen
| | - B G Fulsom
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - N Gabyshev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - E Ganiev
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - M Garcia-Hernandez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - A Garmash
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - V Gaur
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - A Gaz
- INFN Sezione di Padova, I-35131 Padova
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova
| | - A Gellrich
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - R Giordano
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - A Giri
- Indian Institute of Technology Hyderabad, Telangana 502285
| | - A Glazov
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - B Gobbo
- INFN Sezione di Trieste, I-34127 Trieste
| | - R Godang
- University of South Alabama, Mobile, Alabama 36688
| | - P Goldenzweig
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - B Golob
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Grace
- Department of Physics, University of Adelaide, Adelaide, South Australia 5005
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | | | - D Greenwald
- Department of Physics, Technische Universität München, 85748 Garching
| | - Y Guan
- University of Cincinnati, Cincinnati, Ohio 45221
| | - K Gudkova
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - C Hadjivasiliou
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - S Halder
- Tata Institute of Fundamental Research, Mumbai 400005
| | - K Hara
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - O Hartbrich
- University of Hawaii, Honolulu, Hawaii 96822
| | | | | | - S Hazra
- Tata Institute of Fundamental Research, Mumbai 400005
| | - C Hearty
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - I Heredia de la Cruz
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
- Consejo Nacional de Ciencia y Tecnología, Mexico City 03940
| | | | - A Hershenhorn
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - T Higuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - E C Hill
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - H Hirata
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - M Hoek
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - M Hohmann
- School of Physics, University of Melbourne, Victoria 3010
| | - C-L Hsu
- School of Physics, University of Sydney, New South Wales 2006
| | - T Humair
- Max-Planck-Institut für Physik, 80805 München
| | - T Iijima
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - K Inami
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - G Inguglia
- Institute of High Energy Physics, Vienna 1050
| | - J Irakkathil Jabbar
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - A Ishikawa
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - R Itoh
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Iwasaki
- Osaka City University, Osaka 558-8585
| | - Y Iwasaki
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Jackson
- Department of Physics, University of Adelaide, Adelaide, South Australia 5005
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973
| | - Y Jin
- INFN Sezione di Trieste, I-34127 Trieste
| | - C Joo
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | | | - A B Kaliyar
- Tata Institute of Fundamental Research, Mumbai 400005
| | - J Kandra
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - K H Kang
- Kyungpook National University, Daegu 41566
| | - R Karl
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - G Karyan
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - T Kawasaki
- Kitasato University, Sagamihara 252-0373
| | - C Ketter
- University of Hawaii, Honolulu, Hawaii 96822
| | - H Kichimi
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - C Kiesling
- Max-Planck-Institut für Physik, 80805 München
| | - C-H Kim
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - D Y Kim
- Soongsil University, Seoul 06978
| | - Y-K Kim
- Yonsei University, Seoul 03722
| | - T D Kimmel
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - P Kodyš
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - T Koga
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - S Kohani
- University of Hawaii, Honolulu, Hawaii 96822
| | - T Konno
- Kitasato University, Sagamihara 252-0373
| | - A Korobov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - S Korpar
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Chemistry and Chemical Engineering, University of Maribor, 2000 Maribor
| | - E Kovalenko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | | | - F Krinner
- Max-Planck-Institut für Physik, 80805 München
| | - P Križan
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Krokovny
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - T Kuhr
- Ludwig Maximilians University, 80539 Munich
| | - J Kumar
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213
| | - M Kumar
- Malaviya National Institute of Technology Jaipur, Jaipur 302017
| | - R Kumar
- Punjab Agricultural University, Ludhiana 141004
| | - K Kumara
- Wayne State University, Detroit, Michigan 48202
| | - T Kunigo
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - S Kurz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - A Kuzmin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | | | | | - Y-T Lai
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - C La Licata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - L Lanceri
- INFN Sezione di Trieste, I-34127 Trieste
| | - J S Lange
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - M Laurenza
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - K Lautenbach
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | | | - S C Lee
- Kyungpook National University, Daegu 41566
| | - P Leitl
- Max-Planck-Institut für Physik, 80805 München
| | - D Levit
- Department of Physics, Technische Universität München, 85748 Garching
| | | | - C Li
- Liaoning Normal University, Dalian 116029
| | - L K Li
- University of Cincinnati, Cincinnati, Ohio 45221
| | - S X Li
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - Y B Li
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - J Libby
- Indian Institute of Technology Madras, Chennai 600036
| | - K Lieret
- Ludwig Maximilians University, 80539 Munich
| | - Z Liptak
- Hiroshima University, Higashi-Hiroshima, Hiroshima 739-8530
| | - Q Y Liu
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - D Liventsev
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Wayne State University, Detroit, Michigan 48202
| | - S Longo
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - A Lozar
- J. Stefan Institute, 1000 Ljubljana
| | - T Lueck
- Ludwig Maximilians University, 80539 Munich
| | - C Lyu
- University of Bonn, 53115 Bonn
| | - M Maggiora
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - S Maity
- Indian Institute of Technology Bhubaneswar, Satya Nagar 751007
| | - R Manfredi
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia
| | - S Marcello
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - C Marinas
- Instituto de Fisica Corpuscular, Paterna 46980
| | - A Martini
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - M Masuda
- Earthquake Research Institute, University of Tokyo, Tokyo 113-0032
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - T Matsuda
- University of Miyazaki, Miyazaki 889-2192
| | - K Matsuoka
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - D Matvienko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | - F Meier
- Duke University, Durham, North Carolina 27708
| | - M Merola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - F Metzner
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - M Milesi
- School of Physics, University of Melbourne, Victoria 3010
| | - C Miller
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | | | - H Miyake
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - R Mizuk
- National Research University Higher School of Economics, Moscow 101000
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - G B Mohanty
- Tata Institute of Fundamental Research, Mumbai 400005
| | - H-G Moser
- Max-Planck-Institut für Physik, 80805 München
| | - M Mrvar
- Institute of High Energy Physics, Vienna 1050
| | - F J Müller
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - C Murphy
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - R Mussa
- INFN Sezione di Torino, I-10125 Torino
| | - K R Nakamura
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Nakao
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - Z Natkaniec
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342
| | - A Natochii
- University of Hawaii, Honolulu, Hawaii 96822
| | - M Nayak
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, 69978
| | - G Nazaryan
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - C Niebuhr
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N K Nisar
- Brookhaven National Laboratory, Upton, New York 11973
| | - S Nishida
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - K Nishimura
- University of Hawaii, Honolulu, Hawaii 96822
| | - S Ogawa
- Toho University, Funabashi 274-8510
| | - Y Onishchuk
- Taras Shevchenko National University of Kiev, Kiev
| | - H Ono
- Niigata University, Niigata 950-2181
| | - Y Onuki
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - P Oskin
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - H Ozaki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Pakhlov
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Moscow Physical Engineering Institute, Moscow 115409
| | - G Pakhlova
- National Research University Higher School of Economics, Moscow 101000
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - A Paladino
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - T Pang
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260
| | - A Panta
- University of Mississippi, University, Mississippi 38677
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - S Pardi
- INFN Sezione di Napoli, I-80126 Napoli
| | - H Park
- Kyungpook National University, Daegu 41566
| | - S-H Park
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | | | - A Passeri
- INFN Sezione di Roma Tre, I-00146 Roma
| | - A Pathak
- University of Louisville, Louisville, Kentucky 40292
| | - S Patra
- Indian Institute of Science Education and Research Mohali, SAS Nagar, 140306
| | - S Paul
- Department of Physics, Technische Universität München, 85748 Garching
| | | | - I Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | | | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - L E Piilonen
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | | | | | - S Pokharel
- University of Mississippi, University, Mississippi 38677
| | - G Polat
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | - V Popov
- National Research University Higher School of Economics, Moscow 101000
| | - C Praz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Prell
- Iowa State University, Ames, Iowa 50011
| | | | | | - N Rad
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - P Rados
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Raiz
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - M Remnev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - I Ripp-Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - M Ritter
- Ludwig Maximilians University, 80539 Munich
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | | | - S H Robertson
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- McGill University, Montréal, Québec, H3A 2T8
| | | | - J M Roney
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - A Rostomyan
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N Rout
- Indian Institute of Technology Madras, Chennai 600036
| | - G Russo
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - D Sahoo
- Tata Institute of Fundamental Research, Mumbai 400005
| | - D A Sanders
- University of Mississippi, University, Mississippi 38677
| | - S Sandilya
- Indian Institute of Technology Hyderabad, Telangana 502285
| | - A Sangal
- University of Cincinnati, Cincinnati, Ohio 45221
| | - L Santelj
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - Y Sato
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - V Savinov
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260
| | - B Scavino
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - J Schueler
- University of Hawaii, Honolulu, Hawaii 96822
| | - C Schwanda
- Institute of High Energy Physics, Vienna 1050
| | - A J Schwartz
- University of Cincinnati, Cincinnati, Ohio 45221
| | - R M Seddon
- McGill University, Montréal, Québec, H3A 2T8
| | - Y Seino
- Niigata University, Niigata 950-2181
| | - A Selce
- ENEA Casaccia, I-00123 Roma
- INFN Sezione di Roma Tre, I-00146 Roma
| | - K Senyo
- Yamagata University, Yamagata 990-8560
| | - J Serrano
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | - M E Sevior
- School of Physics, University of Melbourne, Victoria 3010
| | - C Sfienti
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - J-G Shiu
- Department of Physics, National Taiwan University, Taipei 10617
| | - B Shwartz
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - A Sibidanov
- University of Hawaii, Honolulu, Hawaii 96822
| | - F Simon
- Max-Planck-Institut für Physik, 80805 München
| | - R J Sobie
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - A Soffer
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, 69978
| | - A Sokolov
- Institute for High Energy Physics, Protvino 142281
| | - E Solovieva
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - S Spataro
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - B Spruck
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - M Starič
- J. Stefan Institute, 1000 Ljubljana
| | - S Stefkova
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - Z S Stottler
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova
| | - M Sumihama
- Gifu University, Gifu 501-1193
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - K Sumisawa
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - D J Summers
- University of Mississippi, University, Mississippi 38677
| | | | - S Y Suzuki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - H Svidras
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - M Tabata
- Chiba University, Chiba 263-8522
| | - M Takahashi
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - M Takizawa
- J-PARC Branch, KEK Theory Center, High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Meson Science Laboratory, Cluster for Pioneering Research, RIKEN, Saitama 351-0198
- Showa Pharmaceutical University, Tokyo 194-8543
| | - U Tamponi
- INFN Sezione di Torino, I-10125 Torino
| | - S Tanaka
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - K Tanida
- Advanced Science Research Center, Japan Atomic Energy Agency, Naka 319-1195
| | - H Tanigawa
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - N Taniguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec, H3C 3J7
| | - F Tenchini
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - D Tonelli
- INFN Sezione di Trieste, I-34127 Trieste
| | - E Torassa
- INFN Sezione di Padova, I-35131 Padova
| | - N Toutounji
- School of Physics, University of Sydney, New South Wales 2006
| | - K Trabelsi
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - M Uchida
- Tokyo Institute of Technology, Tokyo 152-8550
| | - Y Unno
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - K Uno
- Niigata University, Niigata 950-2181
| | - S Uno
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Urquijo
- School of Physics, University of Melbourne, Victoria 3010
| | - Y Ushiroda
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - Y V Usov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - S E Vahsen
- University of Hawaii, Honolulu, Hawaii 96822
| | | | - G S Varner
- University of Hawaii, Honolulu, Hawaii 96822
| | - K E Varvell
- School of Physics, University of Sydney, New South Wales 2006
| | - A Vinokurova
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - L Vitale
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - B Wach
- Max-Planck-Institut für Physik, 80805 München
| | - E Waheed
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | | | - W Wan Abdullah
- National Centre for Particle Physics, University Malaya, 50603 Kuala Lumpur
| | - M-Z Wang
- Department of Physics, National Taiwan University, Taipei 10617
| | - X L Wang
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - A Warburton
- McGill University, Montréal, Québec, H3A 2T8
| | - S Watanuki
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - J Webb
- School of Physics, University of Melbourne, Victoria 3010
| | | | | | | | - H Windel
- Max-Planck-Institut für Physik, 80805 München
| | - X P Xu
- Soochow University, Suzhou 215006
| | - B D Yabsley
- School of Physics, University of Sydney, New South Wales 2006
| | - S Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - W Yan
- University of Science and Technology of China, Hefei 230026
| | | | - H Ye
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - J Yelton
- University of Florida, Gainesville, Florida 32611
| | - J H Yin
- Korea University, Seoul 02841
| | - Y M Yook
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - K Yoshihara
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - C Z Yuan
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - Y Yusa
- Niigata University, Niigata 950-2181
| | - L Zani
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | - V Zhilich
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - Q D Zhou
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
- Institute for Advanced Research, Nagoya University, Nagoya 464-8602
| | - X Y Zhou
- Liaoning Normal University, Dalian 116029
| | - V I Zhukova
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| |
Collapse
|
18
|
Fedele G, Stefanelli P, Bella A, Fiore S, Pancheri S, Benedetti E, Fabiani C, Leone P, Vacca P, Schiavoni I, Neri A, Carannante A, Simmaco M, Santino I, Zuccali MG, Bizzarri G, Magnoni R, Benetollo PP, Brusaferro S, Rezza G, Ferro A. Anti-SARS-CoV-2 antibodies persistence after natural infection: a repeated serosurvey in Northern Italy. Ann Ist Super Sanita 2021; 57:265-271. [PMID: 35076416 DOI: 10.4415/ann_21_04_01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
INTRODUCTION To evaluate the decline of antibodies induced by SARS-CoV-2 infection, the individuals resident in 5 municipalities of the Autonomous Province of Trento, Northern Italy, who resulted IgG positive for anti-SARS-CoV-2 nucleocapsid (NC) in May 2020, were tested four months later. METHODS Anti-SARS-CoV-2 NC antibodies were detected using the Abbott SARS-CoV-2 IgG assay. Samples that gave a negative result were re-tested using the Liaison SARS-CoV-2 IgG assay to assess anti-spike (S) S1/S2 antibodies. The fifty-percent tissue culture infective dose (TCID50) neutralizing assay was performed on a subgroup of formerly positive sera. Statistical analysis was performed by STATA version 16.1 (STATA Corp., College Station, Texas, USA). RESULTS Overall, 480 out of 1159 participants became seronegative for anti-NC IgG antibodies. Age above 70 years and cough were associated with persistent anti-NC IgG levels. Most anti-NC IgG negative sera were positive for anti-S IgG (77.9%). The neutralization assay showed high concordance with anti-S antibodies positivity. CONCLUSION In conclusion, a decline of anti-NC IgG values was recorded four months after the first evaluation. A high proportion of anti-NC seronegative individuals were positive for anti-spike IgG antibodies, which appear to persist longer and to better correlate with neutralization activity.
Collapse
Affiliation(s)
- Giorgio Fedele
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Paola Stefanelli
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Antonino Bella
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Serena Pancheri
- Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy
| | - Eleonora Benedetti
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Concetta Fabiani
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Pasqualina Leone
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Paola Vacca
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Ilaria Schiavoni
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Arianna Neri
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Anna Carannante
- Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy
| | - Maurizio Simmaco
- Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, Facoltà di Medicina e Psicologia, Sapienza Università di Roma, Azienda Ospedaliero-Universitaria Sant'Andrea, Rome Italy
| | - Iolanda Santino
- Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, Facoltà di Medicina e Psicologia, Sapienza Università di Roma, Azienda Ospedaliero-Universitaria Sant'Andrea, Rome Italy
| | | | | | - Rosa Magnoni
- Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy
| | | | | | - Giovanni Rezza
- Direzione Generale della Prevenzione Sanitaria, Ministero della Salute, Rome, Italy
| | - Antonio Ferro
- Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy
| |
Collapse
|
19
|
Severa M, Diotti RA, Etna MP, Rizzo F, Fiore S, Ricci D, Iannetta M, Sinigaglia A, Lodi A, Mancini N, Criscuolo E, Clementi M, Andreoni M, Balducci S, Barzon L, Stefanelli P, Clementi N, Coccia EM. Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. PLoS Pathog 2021; 17:e1009878. [PMID: 34473805 PMCID: PMC8412261 DOI: 10.1371/journal.ppat.1009878] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Accepted: 08/09/2021] [Indexed: 12/25/2022] Open
Abstract
SARS-CoV-2 fine-tunes the interferon (IFN)-induced antiviral responses, which play a key role in preventing coronavirus disease 2019 (COVID-19) progression. Indeed, critically ill patients show an impaired type I IFN response accompanied by elevated inflammatory cytokine and chemokine levels, responsible for cell and tissue damage and associated multi-organ failure. Here, the early interaction between SARS-CoV-2 and immune cells was investigated by interrogating an in vitro human peripheral blood mononuclear cell (PBMC)-based experimental model. We found that, even in absence of a productive viral replication, the virus mediates a vigorous TLR7/8-dependent production of both type I and III IFNs and inflammatory cytokines and chemokines, known to contribute to the cytokine storm observed in COVID-19. Interestingly, we observed how virus-induced type I IFN secreted by PBMC enhances anti-viral response in infected lung epithelial cells, thus, inhibiting viral replication. This type I IFN was released by plasmacytoid dendritic cells (pDC) via an ACE-2-indipendent but Neuropilin-1-dependent mechanism. Viral sensing regulates pDC phenotype by inducing cell surface expression of PD-L1 marker, a feature of type I IFN producing cells. Coherently to what observed in vitro, asymptomatic SARS-CoV-2 infected subjects displayed a similar pDC phenotype associated to a very high serum type I IFN level and induction of anti-viral IFN-stimulated genes in PBMC. Conversely, hospitalized patients with severe COVID-19 display very low frequency of circulating pDC with an inflammatory phenotype and high levels of chemokines and pro-inflammatory cytokines in serum. This study further shed light on the early events resulting from the interaction between SARS-CoV-2 and immune cells occurring in vitro and confirmed ex vivo. These observations can improve our understanding on the contribution of pDC/type I IFN axis in the regulation of the anti-viral state in asymptomatic and severe COVID-19 patients.
Collapse
Affiliation(s)
- Martina Severa
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Roberta A. Diotti
- Laboratory of Medical Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy
| | - Marilena P. Etna
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Fabiana Rizzo
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Daniela Ricci
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Marco Iannetta
- Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy
| | | | - Alessandra Lodi
- Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy
| | - Nicasio Mancini
- Laboratory of Medical Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy
| | - Elena Criscuolo
- Laboratory of Medical Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy
| | - Massimo Clementi
- Laboratory of Medical Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy
| | | | | | - Luisa Barzon
- Department of Molecular Medicine, University of Padova, Padua, Italy
| | - Paola Stefanelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Nicola Clementi
- Laboratory of Medical Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy
| | - Eliana M. Coccia
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| |
Collapse
|
20
|
Dua A, Ford K, Fiore S, Pappas DA, Janak J, Blachley T, Roberts-Toler C, Emeanuru K, Kremer J, Kivitz A. POS0606 DISEASE ACTIVITY AND PATIENTS-REPORTED OUTCOMES AFTER SWITCHING BETWEEN IL-6 RECEPTOR INHIBITORS AND JAK INHIBITORS: AN ANALYSIS FROM THE CORRONA REGISTRY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Rheumatoid arthritis (RA) patients who fail therapy may be switched to any of the five classes of biological disease-modifying antirheumatic drugs (DMARDs) and targeted synthetic DMARDs, to meet treatment goals. Physicians may hesitate to switch between Janus Kinase inhibitors (JAKi) and interleukin-6 receptor inhibitors (IL-6Ri) since they both impact IL-6 signalling and due to limited data on switching between the two classes.Objectives:This retrospective, observational study based on the real-world Corrona RA registry aimed to describe the response in RA patients switching between IL-6Ri and JAKi.Methods:Adult RA patients who initiated either IL-6Ri or JAKi after November 2012 and had a six-month post-initiation follow-up visit were eligible. Patients in ‘Cohort A’ initiated an IL-6Ri following discontinuation of a JAKi and those in ‘Cohort B’ initiated a JAKi following discontinuation of an IL-6Ri. Disease activity measures and patient-reported outcomes (PROs) were evaluated at baseline and at six-month follow-up. Within each group, change from baseline was assessed for Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire (HAQ), pain, fatigue, tender joint count (TJC), swollen joint count (SJC), physician global assessment (MDGA), patient global assessment (PtGA) and morning stiffness duration. Proportion of patients achieving CDAI low disease activity (LDA), CDAI remission and minimal clinically important difference (MCID) for HAQ, pain, fatigue, MDGA, PtGA were assessed. Adjusted linear and logistic regression models were performed for between-group comparisons (Cohort A vs Cohort B) excluding initiators who switched therapy prior to six-month visit.Results:Cohorts A and B included 122 and 144 initiators, respectively. Patients who switched toIL-6Ri (vs JAKi) were younger (mean [SD] age, 56.2 [11.3] vs 58.9 [12.6] years), had higher baseline CDAI (23.2 [12.9] vs 20.2 [12.8]), had higher prior use of ≥2 csDMARDs (75% vs 65%), and were less likely to initiate therapy as monotherapy (44% vs 50%).In Cohort A, significant changes from baseline were observed for all continuous outcomes except HAQ and fatigue. In Cohort B, a significant improvement was observed only for patient-reported pain (Table 1).Table 1.Unadjusted Within-Group Change from Baseline to Six Months, Mean (95% CI), nOutcomesCohort A, N = 122Cohort B, N = 144CDAI-4.7 (-7.6, -1.9), 109-2.4 (-5.2, 0.4), 116HAQ-0.0 (-0.1, 0.1), 105-0.1 (-0.1, 0.0), 118Patient-reported pain-8.2 (-13.4, -3.0), 109-5.9 (-11.5, -0.2), 120Patient-reported fatigue-4.4 (-9.0, 0.2), 109-1.7 (-6.6, 3.3), 117TJC-1.6 (-3.0, -0.1), 112-1.2 (-2.6, 0.3), 117SJC-1.5 (-2.5, -0.4), 112-0.4 (-1.3, 0.6),117MDGA-10.9 (-15.6, -6.3), 112-4.3 (-8.7, 0.2), 117PtGA-6.0 (-11.2, -0.8), 109-4.8 (-10.5, 0.8), 120Morning stiffness durationa-1.3 (-2.2, -0.5), 109-0.1 (-1.1, 0.8), 118aAmong those reporting morning stiffness at baseline.In the adjusted between-group comparison (data not shown) of change from baseline, there were no significant differences in clinical outcomes between Cohorts A and B.In both cohorts, patients achieved CDAI LDA, CDAI remission, and MCIDs across other PROs (Figure 1). In the adjusted between-group comparison (data not shown), the results were similar with the exception of achievement of CDAI LDA among patients with moderate to high disease activity at baseline.Figure 1.Rates of CDAI LDA, CDAI Remission, and MCID for PROsa at Six MonthsConclusion:In general, in both cohorts a substantial proportion of patients achieved CDAI LDA and MCID across PROs. Despite some overlap of JAKi and IL-6Ri therapies’ on the IL-6 pathway, there are some distinct mechanisms of action which may result in meaningful improvements for a subset of patients.Acknowledgements:Amy Praestgaard (Sanofi) contributed to the interpretation of the statistical analysis for this abstract. Medical writing support for this abstract was provided by Nupur Chaubey (Sanofi).Disclosure of Interests:Anisha Dua Speakers bureau: AbbVie, Consultant of: Consulting/advisory board for AbbVie, Novartis, and Chemocentryx, Employee of: Board member of Vasculitis foundation and Chicago Rheumatism Society, Kerri Ford Shareholder of: Sanofi, Employee of: Sanofi, Stefano Fiore Shareholder of: Sanofi, Employee of: Sanofi. In addition, Stefano Fiore has a patent EP 19306553.9; USPTO #s 62/799,698; 62/851,474; 62/935,395 issued, Dimitrios A Pappas Shareholder of: Corrona LLC, Consultant of: Sanofi, AbbVie, Gtech, Roche Hellas, and Novartis, Employee of: Corrona LLC. Board of directors, Corrona Research Foundation, Judson Janak: None declared, Taylor Blachley: None declared, Carla Roberts-Toler: None declared, Kelechi Emeanuru: None declared, Joel Kremer Consultant of: AbbVie, Lilly, Novartis, Pfizer, BMS, Genentech, Regeneron, Sanofi, and Corrona, Grant/research support from: AbbVie, Lilly, Novartis, and Pfizer, Alan Kivitz Shareholder of: Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., and Novartis, Speakers bureau: Celgene, Merck, Lilly, Novartis, Pfizer, Sanofi, Flexion, and AbbVie, Consultant of: AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc. In addition, Alan Kivitz reports other from Altoona Center for Clinical Research, PC, during the conduct of the study.
Collapse
|
21
|
Curtis J, Fiore S, Ford K, Janak J, Chang H, Pappas DA, Blachley T, Emeanuru K, Bykerk V. POS0594 MEANINGFUL IMPROVEMENT AND WORSENING IN PATIENTS WHO DO NOT ACHIEVE LDA AND SWITCH THERAPY TO A NEW BIOLOGIC OR TARGETED THERAPY: RESULTS FROM THE CORRONA REGISTRY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Guidelines recommend adjusting therapy in patients with rheumatoid arthritis (RA) who fail to reach and sustain low disease activity (LDA) or remission (disease control). Many factors can affect the decision to change therapy, including the potential for improvement as well as the fear of potential worsening or loss of improvement already achieved. Although data exist on response to treatment in patients who switch therapy, data addressing the likelihood of worsening are limited.Objectives:The aim of this analysis was to describe the demographic, clinical characteristics, and change in clinical outcomes in patients on biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) who had some improvement in clinical disease activity index (CDAI) but did not achieve LDA after ~ 6-12 months of treatment and then switched to a different b/tsDMARD.Methods:This study included adult inadequately responding RA patients from the CORRONA registry who: (1) started a biologic or Janus kinase inhibitor (JAKi) between January 2010 to November 2020 (V1), (2) had any CDAI improvement (i.e., decrease ≥1 unit) but were not in LDA or remission at a subsequent visit (baseline [BL]) occurring 3 to 15 months after V1; (3) had a third visit (follow-up [F/U]) 6 (±3) months after BL with a valid CDAI measure; (4) switched therapy at the BL or between BL and F/U, with the switch occurring at least 3 months prior to the F/U. CDAI >10 and ≤22 was defined as moderate disease activity (MDA) and CDAI >22 was defined as high disease activity (HDA). Two thresholds of change in CDAI (≥6 and ≥12 units) were used to define meaningful improvement and meaningful worsening after the switch. If there was no meaningful improvement or meaningful worsening, this was considered as no meaningful change (-5 to +5 for 6 units change and -11 to +11 for 12 units change). These thresholds for meaningful change were set for all switchers regardless of their pre-switch CDAI value. Descriptive statistics were generated for demographic and clinical characteristics for the switchers at BL, and the change of clinical outcomes was evaluated from BL to F/U.Results:Of the 1,224 patients fulfilling the inclusion criteria, 93 (7.6%) switched therapy and 1,131 (92.4%) did not switch therampy after not achieving an adequate response on the initial b/tsDMARD. At BL, 42.5% and 70.0% of patients had no meaningful improvement to their prior therapy based on ≥6 and ≥12-unit change, respectively; mean (SD) age was 53.1 (14.0) years; duration of RA 10.7 (10.4) years; CDAI 22.2 (10.8); 81.7% were female; 64.5% had MDA, 35.5% had HDA; 21.5 % reported being disabled, 24.7% were current smokers, and 50% were obese. In terms of prior biologic use 57.0%, 22.6%, and 20.4% had been on 1, 2, and 3+, respectively. From BL to F/U, meaningful worsening occurred in 30.1% and 12.9% using a threshold of 6 and 12, respectively, with the remaining patients experiencing meaningful improvement or no meaningful change (Figure 1).Figure 1.Meaningful Worsening, Meaningful Improvement, and No Meaningful Change Based on CDAI Change Thresholds of ≥6 and ≥12 From BL to F/U (N=93)Conclusion:In our analysis, a large proportion of patients who initiated a biologic/JAKi and experienced some improvement but failed to attain LDA or remission, did not switch therapy within approximately a year. This analysis consisted of many patients who did not have a meaningful response to their prior biologic/JAKi, patients who had received multiple prior biologics, and a large portion of patients with poor prognostic factors. Despite this, the proportion of patients with meaningful worsening was low compared with most patients who had either meaningful improvement or no meaningful change. Additional research is warranted to understand the reasons for not switching and whether the likelihood of a meaningful change correlates with prior response, poor prognosis, or other factors.Acknowledgements:Amy Praestgaard (Sanofi) contributed to the statistical analysis for this abstract. Medical writing support for this abstract was provided by Krishna Kammari (Sanofi).Disclosure of Interests:Jeffrey Curtis Grant/research support from: and personal fees from AbbVie, Amgen, BMS, CORRONA, Eli Lily, Janssen, Myriad, Pfizer, Roche, Regeneron, Radius, UCB, outside the submitted work, Stefano Fiore Shareholder of: Sanofi, Employee of: Sanofi. In addition, he has a patent EP 19306553.9; USPTO #s 62/799,698; 62/851,474; 62/935,395 issued, Kerri Ford Shareholder of: Sanofi, Employee of: Sanofi, Judson Janak: None declared, Hong Chang: None declared, Dimitrios A Pappas Employee of: CORRONA LLC. He has previously acted as a consultant for Sanofi, Abbvie, Gtech Roche Hellas, and Novartis. He has an equity interest in CORRONA LLC. and is on the Board of directors of the CORRONA research foundation, Taylor Blachley: None declared, Kelechi Emeanuru: None declared, Vivian Bykerk Grant/research support from: reports grants from Amgen, BMS, UCB, and Novartis were given to institution, that grants from the NIH, PCORI, and CIHR were given to institutions which whom she is affiliated, and that she has received personal fees from Amgen, Gilead, BMS, Pfizer, Sanofi Aventis, Roche, UCB and Regeneron, outside the submitted work.
Collapse
|
22
|
Fiore S, Chen L, Clinton C, Yun H, Praestgaard A, Ford K, Curtis J. POS0638 DISEASE SEVERITY AND OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS WHO RECEIVE A NEWLY APPROVED BIOLOGIC: REAL-WORLD US EXPERIENCE WITH SARILUMAB FROM THE ACR RISE REGISTRY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Patients with rheumatoid arthritis (RA) who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may lead to worse clinical response to treatment.Objectives:We used data from the ACR RISE registry to assess whether disease severity was greater in those who received sarilumab shortly after its FDA approval (May 2017) than in subsequent time periods and to evaluate the effectiveness of sarilumab in populations with various degrees of disease severity.Methods:Patients with RA who initiated sarilumab treatment in the period 2017-2020 were identified in the ACR RISE registry and divided into Cohort 1 (2017, year of the FDA approval) and the calendar year-based Cohorts 2-4 (2018-2020). Patient demographics, RA-related features, and comorbidities were determined using data prior to sarilumab initiation. The cohorts were compared using chi-square test (categorical variables) and a nonparametric test (continuous variables). Sarilumab effectiveness was assessed using 3 cohorts assembled based on progressively restrictive criteria: Active Disease cohort (Clinical Disease Activity Index [CDAI] >10 or Routine Assessment of Patient Index Data 3 [RAPID3] >6, and C-reactive protein, if measured, ≥8 mg/L), TARGET Eligibility cohort (patients who satisfied enrolment criteria for TARGET,1 a Phase 3 sarilumab trial in patients with RA and an inadequate response to TNF inhibitors), and TARGET Baseline cohort (patients from TARGET Eligibility cohort with characteristics weighted to match those from the TARGET trial baseline,1 using the matching-adjusted indirect comparison method2). In all 3 effectiveness cohorts, mean changes in CDAI and RAPID3 at 6 and 12 months post-initiation of sarilumab were evaluated using a model adjusted for baseline score, age, sex, race, calendar year, and seropositivity.Results:A total of 2949 patients, treated by 585 rheumatologists, initiated sarilumab treatment in the period 2017–2020. The 4 yearly cohorts were relatively similar in terms of patients’ age, sex, race, and most clinical characteristics. However, patients receiving sarilumab shortly after FDA approval (Cohort 1) had more ambulatory visits, a greater number of previously used non-TNFi biologics (particularly tocilizumab), and a higher comorbidity burden, and were more likely to be current users of glucocorticoids or opioids than sarilumab initiators in the subsequent 3 years. In the 3 cohorts used to assess sarilumab effectiveness, the greatest improvement was observed in the TARGET Baseline cohort, which also had the greatest mean baseline CDAI score (43), compared with the other two (24 both).Conclusion:In this real-world cohort, we observed modest evidence for channeling of patients with greater RA severity and greater prior exposure to non-TNFi biologics to sarilumab shortly after its FDA approval. This cohort effect did not diminish the effectiveness of sarilumab. All cohorts showed improvement, with the greatest clinical improvement observed in the cohort with the highest baseline CDAI score who most closely resembled those enrolled in a phase 3 trial of patients with an inadequate response to TNF inhibitors.References:[1]Fleischmann R, et al. Arthritis Rheumatol 2017;69:277-290.[2]Signorovitch JE et al. Value Health 2012;15:940-7.Figure 1.Adjusted improvements in CDAI and RAPID3Acknowledgements:This study was sponsored by Sanofi. Medical writing support was provided by Vojislav Pejović, PhD (Eloquent Medical Affairs, division of Envision Pharma Group) and funded by Sanofi.Disclosure of Interests:Stefano Fiore Employee of: Sanofi, Lang Chen: None declared, Cassie Clinton Consultant of: Information available in profile, Huifeng Yun Grant/research support from: Research support for Pfizer, Amy Praestgaard Employee of: Sanofi, Kerri Ford Employee of: Sanofi, Jeffrey Curtis Consultant of: Received consulting and research grants from AbbVie, Amgen, BMS, Lilly, Gilead, GSK, Janssen, Myriad, Pfizer, Roche, Samsung, Sandoz, Sanofi, UCB, Grant/research support from: Received consulting and research grants from AbbVie, Amgen, BMS, Lilly, Gilead, GSK, Janssen, Myriad, Pfizer, Roche, Samsung, Sandoz, Sanofi, UCB
Collapse
|
23
|
Gatti M, Palmisano A, Esposito A, Fiore S, Monti CB, Andreis A, Pistelli L, Vergara P, Bergamasco L, Giustetto C, De Cobelli F, Fonio P, Faletti R. Feature tracking myocardial strain analysis in patients with bileaflet mitral valve prolapse: relationship with LGE and arrhythmias. Eur Radiol 2021; 31:7273-7282. [PMID: 33870458 DOI: 10.1007/s00330-021-07876-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2020] [Revised: 03/06/2021] [Accepted: 03/12/2021] [Indexed: 12/11/2022]
Abstract
OBJECTIVES Anatomical substrate and mechanical trigger co-act in arrhythmia's onset in patients with bileaflet mitral valve prolapse (bMVP). Feature tracking (FT) may improve risk stratification provided by cardiac magnetic resonance (CMR). The aim was to investigate differences in CMR and FT parameters in bMVP patients with and without complex arrhythmias (cVA and no-cVA). METHODS In this retrospective study, 52 patients with bMVP underwent 1.5 T CMR and were classified either as no-cVA (n = 32; 12 males; 49.6 ± 17.4 years) or cVA (n = 20; 3 males; 44.7 ± 11.2 years), the latter group including 6 patients (1 male; 45.7 ± 12.7 years) with sustained ventricular tachycardia or ventricular fibrillation (SVT-FV). Twenty-four healthy volunteers (11 males, 36.2 ± 12.5 years) served as control. Curling, prolapse distance, mitral annulus disjunction (MAD), and late gadolinium enhancement (LGE) were recorded and CMR-FT analysis performed. Statistical analysis included non-parametric tests and binary logistic regression. RESULTS LGE and MAD distance were associated with cVA with an odds ratio (OR) of 8.51 for LGE (95% CI 1.76, 41.28; p = 0.008) and of 1.25 for MAD (95% CI 1.02, 1.54; p = 0.03). GLS 2D (- 11.65 ± 6.58 vs - 16.55 ± 5.09 1/s; p = 0.04), PSSR longitudinal 2D (0.04 ± 1.62 1/s vs - 1.06 ± 0.35 1/s; p = 0.0001), and PSSR radial 3D (3.95 ± 1.97 1/s vs 2.64 ± 1.03 1/s; p = 0.0001) were different for SVT-VF versus the others. PDSR circumferential 2D (1.10 ± 0.54 vs. 0.84 ± 0.34 1/s; p = 0.04) and 3D (0.94 ± 0.42 vs. 0.69 ± 0.17 1/s; p = 0.04) differed between patients with and without papillary muscle LGE. CONCLUSIONS CMR-FT allowed identifying subtle myocardial deformation abnormalities in bMVP patients at risk of SVT-VF. LGE and MAD distance were associated with cVA. KEY POINTS • CMR-FT allows identifying several subtle myocardial deformation abnormalities in bMVP patients, especially those involving the papillary muscle. • CMR-FT allows identifying subtle myocardial deformation abnormalities in bMVP patients at risk of SVT and VF. • In patients with bMVP, the stronger predictor of cVA is LGE (OR = 8.51; 95% CI 1.76, 41.28; p = 0.008), followed by MAD distance (OR = 1.25; 95% CI 1.02, 1.54; p = 0.03).
Collapse
Affiliation(s)
- Marco Gatti
- Radiology Unit, Department of Surgical Sciences, University of Turin, Turin, Italy
| | - Anna Palmisano
- Experimental Imaging Centre, Radiology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.,School of Medicine, Vita-Salute San Raffaele University, Milan, Italy
| | - Antonio Esposito
- Experimental Imaging Centre, Radiology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. .,School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
| | - Stefano Fiore
- Radiology Unit, Department of Surgical Sciences, University of Turin, Turin, Italy
| | - Caterina Beatrice Monti
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy
| | - Alessandro Andreis
- Division of Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Lorenzo Pistelli
- Division of Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Pasquale Vergara
- Arrhythmias and Cardiac Electrophysiology, Ospedale San Raffaele, Milan, Italy
| | - Laura Bergamasco
- Department of Surgical Sciences, University of Turin, Turin, Italy
| | - Carla Giustetto
- Division of Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Francesco De Cobelli
- Experimental Imaging Centre, Radiology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.,School of Medicine, Vita-Salute San Raffaele University, Milan, Italy
| | - Paolo Fonio
- Radiology Unit, Department of Surgical Sciences, University of Turin, Turin, Italy
| | - Riccardo Faletti
- Radiology Unit, Department of Surgical Sciences, University of Turin, Turin, Italy
| |
Collapse
|
24
|
Farinelli R, Balossino I, Bencivenni G, Cibinetto G, Felici G, Fiore S, Garzia I, Gatta M, Giovannetti M, Hall-Wilton R, Lai CC, Lavezzi L, Mezzadri G, Morello G, Paoletti E, Papalino G, Pietropaolo A, Pillon M, Poli Lener M, Robinson L, Scodeggio M, Svensson P. µRANIA-V: an innovative solution for neutron detection in homeland security. EPJ Web Conf 2021. [DOI: 10.1051/epjconf/202125307009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Detection of neutrons is becoming of the utmost importance, especially in the studies of radioactive waste and in homeland security applications. The crisis of 3He availability has required the development of innovative techniques. One solution is to develop light gas detectors for neutron counting to be used as portals for ports and airports. The neutron is converted on the Boron-coated cathode, releasing a charged particle, whose passage can be identified by the gas detector. While several technologies have been deployed in the past, the project μRANIA-V (μRwell Advanced Neutron Identification Apparatus) aims to detect thermal neutrons by means of the μRwell technology, an innovative gas detector. The goal is to produce tiles to operate as portals in homeland security or for radioactive waste management. The technological transfer towards the industry has started, thus the production can be cost-effective also owing to a construction process relatively easier compared to similar apparatus. By reading directly the signals from the amplification stage, the neutrons can be counted with simplified electronics further reducing the total cost. In this paper, the project will be described, with details on the μRwell technology and on the neutron counting, on the test beam performed, and on the future plans.
Collapse
|
25
|
Stefanelli P, Bella A, Fedele G, Pancheri S, Leone P, Vacca P, Neri A, Carannante A, Fazio C, Benedetti E, Fiore S, Fabiani C, Simmaco M, Santino I, Zuccali MG, Bizzarri G, Magnoni R, Benetollo PP, Merler S, Brusaferro S, Rezza G, Ferro A. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study. Clin Microbiol Infect 2020; 27:633.e1-633.e7. [PMID: 33253941 PMCID: PMC7695553 DOI: 10.1016/j.cmi.2020.11.013] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Revised: 10/28/2020] [Accepted: 11/17/2020] [Indexed: 01/13/2023]
Abstract
Objectives A seroprevalence study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was conducted in a high-incidence area located in northeastern Italy. Methods All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases, were invited to participate in the study. Among 6098 participants, 6075 sera and a standardized questionnaire administered face-to-face were collected between 5 May and 15 May 2020 and examined. Symptomatic individuals and their family contacts were tested by RT-PCR. Anti-SARS-CoV-2 antibodies were detected using an Abbott SARS-CoV-2 IgG assay, which was performed on the Abbott Architect i2000SR automated analyser. Seroprevalence was calculated as the proportion of positive results among the total number tested. A multivariable logistic regression model was performed to assess the relationship between seropositive versus seronegative individuals for a set of explanatory variables. Results A total of 1402 participants were positive for IgG antibodies against SARS-CoV-2, with a prevalence of 23.1% (1402/6075). The highest prevalence was found in the age class 40–49 years. Overall, 34.4% (2096/6098) of the participants reported at least one symptom. The ratio between reported cases identified by molecular test and those with seropositive results was 1:3, with a maximum ratio of about 1:7 in the age group <20 years and a minimum around 1:1 in those >70 years old. The infection fatality rate was 2.5% (35/1402). Among the symptoms, anosmia and ageusia were strongly associated with seropositivity. Conclusions The estimated seroprevalence of 23% was three-fold higher than the number of cases reported in the COVID-19 Integrated Surveillance data in the study area. This may be explained in part by a relatively high number of individuals presenting mild or no illness, especially those of younger age, and people who did not seek medical care or testing, but who may contribute to virus transmission in the community.
Collapse
Affiliation(s)
- Paola Stefanelli
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
| | - Antonino Bella
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Giorgio Fedele
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Serena Pancheri
- APSS (Azienda Provinciale per i Servizi Sanitari), Trento, Italy
| | - Pasqualina Leone
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Paola Vacca
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Arianna Neri
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Anna Carannante
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Cecilia Fazio
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Eleonora Benedetti
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Concetta Fabiani
- Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Maurizio Simmaco
- Hospital Direction and Clinical Departments, Sant'Andrea University Hospital, Rome, Italy
| | - Iolanda Santino
- Hospital Direction and Clinical Departments, Sant'Andrea University Hospital, Rome, Italy
| | | | | | - Rosa Magnoni
- APSS (Azienda Provinciale per i Servizi Sanitari), Trento, Italy
| | | | - Stefano Merler
- Center for Information Technology, Bruno Kessler Foundation, Trento, Italy
| | | | - Giovanni Rezza
- Health Prevention Directorate, Ministry of Health, Rome, Italy
| | - Antonio Ferro
- APSS (Azienda Provinciale per i Servizi Sanitari), Trento, Italy
| |
Collapse
|
26
|
Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Response to ‘Correspondence on ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’’ by Zheng et al. Ann Rheum Dis 2020; 81:e225. [DOI: 10.1136/annrheumdis-2020-218907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Accepted: 09/04/2020] [Indexed: 11/03/2022]
|
27
|
Abudinén F, Adachi I, Aihara H, Akopov N, Aloisio A, Ameli F, Anh Ky N, Asner DM, Aushev T, Aushev V, Babu V, Baehr S, Bahinipati S, Bambade P, Banerjee S, Bansal S, Baudot J, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertemes M, Bessner M, Bettarini S, Bhardwaj V, Bianchi F, Bilka T, Bilokin S, Biswas D, Bračko M, Branchini P, Braun N, Browder TE, Budano A, Bussino S, Campajola M, Casarosa G, Cecchi C, Červenkov D, Chang MC, Chang P, Cheaib R, Chekelian V, Cheon BG, Chilikin K, Chirapatpimol K, Cho HE, Cho K, Cho SJ, Choi SK, Cinabro D, Corona L, Cremaldi LM, Cunliffe S, Dash N, Dattola F, De La Cruz-Burelo E, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, De Yta-Hernandez A, Di Capua F, Doležal Z, Dong TV, Dort K, Dossett D, Dujany G, Eidelman S, Ferber T, Ferlewicz D, Fiore S, Fodor A, Forti F, Fulsom BG, Ganiev E, Garg R, Garmash A, Gaur V, Gaz A, Gebauer U, Gellrich A, Geßler T, Giordano R, Giri A, Gobbo B, Godang R, Goldenzweig P, Golob B, Gomis P, Gradl W, Graziani E, Greenwald D, Hadjivasiliou C, Halder S, Hartbrich O, Hayasaka K, Hayashii H, Hearty C, Hedges MT, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hirata H, Hoek M, Hohmann M, Hsu CL, Hu Y, Inami K, Inguglia G, Irakkathil Jabbar J, Ishikawa A, Itoh R, Jackson P, Jacobs WW, Jaffe DE, Jang EJ, Jia S, Jin Y, Joo C, Kaliyar AB, Kandra J, Karyan G, Kato Y, Kichimi H, Kiesling C, Kim CH, Kim DY, Kim HJ, Kim SH, Kim YK, Kimmel TD, Kinoshita K, Kleinwort C, Kodyš P, Koga T, Kohani S, Komarov I, Korpar S, Kraetzschmar TMG, Križan P, Krokovny P, Kuhr T, Kumar M, Kumar R, Kumara K, Kurz S, Kwon YJ, Lacaprara S, La Licata C, Lanceri L, Lange JS, Lee IS, Lee SC, Leitl P, Levit D, Lewis PM, Li C, Li LK, Li YB, Libby J, Lieret K, Li Gioi L, Liptak Z, Liu QY, Liventsev D, Longo S, Luo T, MacQueen C, Maeda Y, Manfredi R, Manoni E, Marcello S, Marinas C, Martini A, Masuda M, Matsuoka K, Matvienko D, Meggendorfer F, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Mizuk R, Azmi K, Mohanty GB, Moser HG, Mrvar M, Müller FJ, Mussa R, Nakamura I, Nakao M, Nakazawa H, Natochii A, Niebuhr C, Nisar NK, Nishida S, Nouxman MHA, Ogawa K, Ogawa S, Ono H, Oskin P, Ozaki H, Pakhlov P, Paladino A, Panta A, Paoloni E, Pardi S, Park H, Park SH, Paschen B, Passeri A, Pathak A, Patra S, Paul S, Pedlar TK, Peruzzi I, Peschke R, Piccolo M, Piilonen LE, Polat G, Popov V, Praz C, Prencipe E, Prim MT, Purohit MV, Rad N, Rados P, Rasheed R, Reif M, Reiter S, Remnev M, Ripp-Baudot I, Ritter M, Ritzert M, Rizzo G, Robertson SH, Rodríguez Pérez D, Roney JM, Rosenfeld C, Rostomyan A, Rout N, Sahoo D, Sakai Y, Sanders DA, Sandilya S, Sangal A, Santelj L, Sato Y, Savinov V, Scavino B, Schwanda C, Schwartz AJ, Seddon RM, Seino Y, Selce A, Senyo K, Serrano J, Sevior ME, Sfienti C, Shiu JG, Sibidanov A, Simon F, Sobie RJ, Soffer A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Strube J, Sumihama M, Sumiyoshi T, Summers DJ, Sutcliffe W, Svidras H, Tabata M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Tanigawa H, Taras P, Tenchini F, Tonelli D, Torassa E, Trabelsi K, Uchida M, Uglov T, Unger K, Unno Y, Uno S, Urquijo P, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Waheed E, Wakai M, Wakeling HM, Wang CH, Wang MZ, Wang XL, Warburton A, Watanabe M, Watanuki S, Webb J, Wehle S, Welsch M, Wessel C, Wiechczynski J, Windel H, Won E, Wu LJ, Xu XP, Yabsley B, Yan W, Yang SB, Ye H, Yonenaga M, Yuan CZ, Yusa Y, Zani L, Zhou QD, Zhukova VI. Search for Axionlike Particles Produced in e^{+}e^{-} Collisions at Belle II. Phys Rev Lett 2020; 125:161806. [PMID: 33124872 DOI: 10.1103/physrevlett.125.161806] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Accepted: 09/08/2020] [Indexed: 06/11/2023]
Abstract
We present a search for the direct production of a light pseudoscalar a decaying into two photons with the Belle II detector at the SuperKEKB collider. We search for the process e^{+}e^{-}→γa, a→γγ in the mass range 0.2<m_{a}<9.7 GeV/c^{2} using data corresponding to an integrated luminosity of (445±3) pb^{-1}. Light pseudoscalars interacting predominantly with standard model gauge bosons (so-called axionlike particles or ALPs) are frequently postulated in extensions of the standard model. We find no evidence for ALPs and set 95% confidence level upper limits on the coupling strength g_{aγγ} of ALPs to photons at the level of 10^{-3} GeV^{-1}. The limits are the most restrictive to date for 0.2<m_{a}<1 GeV/c^{2}.
Collapse
Affiliation(s)
- F Abudinén
- INFN Sezione di Trieste, I-34127 Trieste
| | - I Adachi
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - H Aihara
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - N Akopov
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - A Aloisio
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - F Ameli
- INFN Sezione di Roma, I-00185 Roma
| | - N Anh Ky
- Institute of Theoretical and Applied Research (ITAR), Duy Tan University, Hanoi 100000
- Institute of Physics, Vietnam Academy of Science and Technology (VAST), Hanoi
| | - D M Asner
- Brookhaven National Laboratory, Upton, New York 11973
| | - T Aushev
- Higher School of Economics (HSE), Moscow 101000
| | - V Aushev
- Taras Shevchenko National University of Kiev, Kiev
| | - V Babu
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Baehr
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - S Bahinipati
- Indian Institute of Technology Bhubaneswar, Satya Nagar 751007
| | - P Bambade
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292
| | - S Bansal
- Panjab University, Chandigarh 160014
| | - J Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - J Becker
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - P K Behera
- Indian Institute of Technology Madras, Chennai 600036
| | - J V Bennett
- University of Mississippi, University, Mississippi 38677
| | | | | | - M Bertemes
- Institute of High Energy Physics, Vienna 1050
| | - M Bessner
- University of Hawaii, Honolulu, Hawaii 96822
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - V Bhardwaj
- Indian Institute of Science Education and Research Mohali, SAS Nagar, 140306
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - T Bilka
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - S Bilokin
- Ludwig Maximilians University, 80539 Munich
| | - D Biswas
- University of Louisville, Louisville, Kentucky 40292
| | - M Bračko
- J. Stefan Institute, 1000 Ljubljana
- University of Maribor, 2000 Maribor
| | | | - N Braun
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - T E Browder
- University of Hawaii, Honolulu, Hawaii 96822
| | - A Budano
- INFN Sezione di Roma Tre, I-00146 Roma
| | - S Bussino
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - M Campajola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - C Cecchi
- INFN Sezione di Perugia, I-06123 Perugia
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia
| | - D Červenkov
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - M-C Chang
- Department of Physics, Fu Jen Catholic University, Taipei 24205
| | - P Chang
- Department of Physics, National Taiwan University, Taipei 10617
| | - R Cheaib
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | - V Chekelian
- Max-Planck-Institut für Physik, 80805 München
| | - B G Cheon
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - K Chilikin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | | | - H-E Cho
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - K Cho
- Korea Institute of Science and Technology Information, Daejeon 34141
| | - S-J Cho
- Yonsei University, Seoul 03722
| | - S-K Choi
- Gyeongsang National University, Jinju 52828
| | - D Cinabro
- Wayne State University, Detroit, Michigan 48202
| | - L Corona
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - L M Cremaldi
- University of Mississippi, University, Mississippi 38677
| | - S Cunliffe
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N Dash
- Indian Institute of Technology Madras, Chennai 600036
| | - F Dattola
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - E De La Cruz-Burelo
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - G De Nardo
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - M De Nuccio
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - M Destefanis
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - A De Yta-Hernandez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - F Di Capua
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - Z Doležal
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - T V Dong
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - K Dort
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - D Dossett
- School of Physics, University of Melbourne, Victoria 3010
| | - G Dujany
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - S Eidelman
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | - T Ferber
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - D Ferlewicz
- School of Physics, University of Melbourne, Victoria 3010
| | - S Fiore
- INFN Sezione di Roma, I-00185 Roma
| | - A Fodor
- McGill University, Montréal, Québec, H3A 2T8
| | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - B G Fulsom
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - E Ganiev
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - R Garg
- Panjab University, Chandigarh 160014
| | - A Garmash
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - V Gaur
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - A Gaz
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - U Gebauer
- II. Physikalisches Institut, Georg-August-Universität Göttingen, 37073 Göttingen
| | - A Gellrich
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - T Geßler
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - R Giordano
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - A Giri
- Indian Institute of Technology Hyderabad, Telangana 502285
| | - B Gobbo
- INFN Sezione di Trieste, I-34127 Trieste
| | - R Godang
- University of South Alabama, Mobile, Alabama 36688
| | - P Goldenzweig
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - B Golob
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Gomis
- Instituto de Fisica Corpuscular, Paterna 46980
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | | | - D Greenwald
- Department of Physics, Technische Universität München, 85748 Garching
| | - C Hadjivasiliou
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - S Halder
- Tata Institute of Fundamental Research, Mumbai 400005
| | - O Hartbrich
- University of Hawaii, Honolulu, Hawaii 96822
| | | | | | - C Hearty
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | - M T Hedges
- University of Hawaii, Honolulu, Hawaii 96822
| | - I Heredia de la Cruz
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
- Consejo Nacional de Ciencia y Tecnología, Mexico City 03940
| | | | - A Hershenhorn
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | - T Higuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - E C Hill
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | - H Hirata
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - M Hoek
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - M Hohmann
- School of Physics, University of Melbourne, Victoria 3010
| | - C-L Hsu
- School of Physics, University of Sydney, New South Wales 2006
| | - Y Hu
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - K Inami
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - G Inguglia
- Institute of High Energy Physics, Vienna 1050
| | - J Irakkathil Jabbar
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - A Ishikawa
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - R Itoh
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Jackson
- Department of Physics, University of Adelaide, Adelaide, South Australia 5005
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973
| | - E-J Jang
- Gyeongsang National University, Jinju 52828
| | - S Jia
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - Y Jin
- INFN Sezione di Trieste, I-34127 Trieste
| | - C Joo
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - A B Kaliyar
- Tata Institute of Fundamental Research, Mumbai 400005
| | - J Kandra
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - G Karyan
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - Y Kato
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - H Kichimi
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - C Kiesling
- Max-Planck-Institut für Physik, 80805 München
| | - C-H Kim
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - D Y Kim
- Soongsil University, Seoul 06978
| | - H J Kim
- Kyungpook National University, Daegu 41566
| | - S-H Kim
- Seoul National University, Seoul 08826
| | - Y-K Kim
- Yonsei University, Seoul 03722
| | - T D Kimmel
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - K Kinoshita
- University of Cincinnati, Cincinnati, Ohio 45221
| | - C Kleinwort
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - P Kodyš
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - T Koga
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - S Kohani
- University of Hawaii, Honolulu, Hawaii 96822
| | - I Komarov
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Korpar
- J. Stefan Institute, 1000 Ljubljana
- University of Maribor, 2000 Maribor
| | | | - P Križan
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Krokovny
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - T Kuhr
- Ludwig Maximilians University, 80539 Munich
| | - M Kumar
- Malaviya National Institute of Technology Jaipur, Jaipur 302017
| | - R Kumar
- Punjab Agricultural University, Ludhiana 141004
| | - K Kumara
- Wayne State University, Detroit, Michigan 48202
| | - S Kurz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | | | - C La Licata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - L Lanceri
- INFN Sezione di Trieste, I-34127 Trieste
| | - J S Lange
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - I-S Lee
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - S C Lee
- Kyungpook National University, Daegu 41566
| | - P Leitl
- Max-Planck-Institut für Physik, 80805 München
| | - D Levit
- Department of Physics, Technische Universität München, 85748 Garching
| | | | - C Li
- Liaoning Normal University, Dalian 116029
| | - L K Li
- University of Cincinnati, Cincinnati, Ohio 45221
| | - Y B Li
- Peking University, Beijing 100871
| | - J Libby
- Indian Institute of Technology Madras, Chennai 600036
| | - K Lieret
- Ludwig Maximilians University, 80539 Munich
| | - L Li Gioi
- Max-Planck-Institut für Physik, 80805 München
| | - Z Liptak
- University of Hawaii, Honolulu, Hawaii 96822
| | - Q Y Liu
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - D Liventsev
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Wayne State University, Detroit, Michigan 48202
| | - S Longo
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - T Luo
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - C MacQueen
- School of Physics, University of Melbourne, Victoria 3010
| | - Y Maeda
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - R Manfredi
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia
| | - S Marcello
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - C Marinas
- Instituto de Fisica Corpuscular, Paterna 46980
| | - A Martini
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - M Masuda
- Earthquake Research Institute, University of Tokyo, Tokyo 113-0032
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - K Matsuoka
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - D Matvienko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | | | - F Meier
- Duke University, Durham, North Carolina 27708
| | - M Merola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Agraria, Università di Napoli Federico II, I-80055 Portici (NA)
| | - F Metzner
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - M Milesi
- School of Physics, University of Melbourne, Victoria 3010
| | - C Miller
- University of Victoria, Victoria, British Columbia V8W 3P6
| | | | - R Mizuk
- Higher School of Economics (HSE), Moscow 101000
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - K Azmi
- National Centre for Particle Physics, University Malaya, 50603 Kuala Lumpur
| | - G B Mohanty
- Tata Institute of Fundamental Research, Mumbai 400005
| | - H-G Moser
- Max-Planck-Institut für Physik, 80805 München
| | - M Mrvar
- Institute of High Energy Physics, Vienna 1050
| | - F J Müller
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - R Mussa
- INFN Sezione di Torino, I-10125 Torino
| | - I Nakamura
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Nakao
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - H Nakazawa
- Department of Physics, National Taiwan University, Taipei 10617
| | - A Natochii
- University of Hawaii, Honolulu, Hawaii 96822
| | - C Niebuhr
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N K Nisar
- Brookhaven National Laboratory, Upton, New York 11973
| | - S Nishida
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M H A Nouxman
- National Centre for Particle Physics, University Malaya, 50603 Kuala Lumpur
| | - K Ogawa
- Niigata University, Niigata 950-2181
| | - S Ogawa
- Toho University, Funabashi 274-8510
| | - H Ono
- Niigata University, Niigata 950-2181
| | - P Oskin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - H Ozaki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Pakhlov
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Moscow Physical Engineering Institute, Moscow 115409
| | - A Paladino
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - A Panta
- University of Mississippi, University, Mississippi 38677
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - S Pardi
- INFN Sezione di Napoli, I-80126 Napoli
| | - H Park
- Kyungpook National University, Daegu 41566
| | | | | | - A Passeri
- INFN Sezione di Roma Tre, I-00146 Roma
| | - A Pathak
- University of Louisville, Louisville, Kentucky 40292
| | - S Patra
- Indian Institute of Science Education and Research Mohali, SAS Nagar, 140306
| | - S Paul
- Department of Physics, Technische Universität München, 85748 Garching
| | | | - I Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - R Peschke
- University of Hawaii, Honolulu, Hawaii 96822
| | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - L E Piilonen
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - G Polat
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | - V Popov
- Higher School of Economics (HSE), Moscow 101000
| | - C Praz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | - M T Prim
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - M V Purohit
- Okinawa Institute of Science and Technology, Okinawa 904-0495
| | - N Rad
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - P Rados
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - R Rasheed
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - M Reif
- Max-Planck-Institut für Physik, 80805 München
| | - S Reiter
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - M Remnev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - I Ripp-Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - M Ritter
- Ludwig Maximilians University, 80539 Munich
| | - M Ritzert
- University of Heidelberg, 68131 Mannheim
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - S H Robertson
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- McGill University, Montréal, Québec, H3A 2T8
| | | | - J M Roney
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of Victoria, Victoria, British Columbia V8W 3P6
| | - C Rosenfeld
- University of South Carolina, Columbia, South Carolina 29208
| | - A Rostomyan
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N Rout
- Indian Institute of Technology Madras, Chennai 600036
| | - D Sahoo
- Tata Institute of Fundamental Research, Mumbai 400005
| | - Y Sakai
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - D A Sanders
- University of Mississippi, University, Mississippi 38677
| | - S Sandilya
- University of Cincinnati, Cincinnati, Ohio 45221
| | - A Sangal
- University of Cincinnati, Cincinnati, Ohio 45221
| | - L Santelj
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - Y Sato
- Department of Physics, Tohoku University, Sendai 980-8578
| | - V Savinov
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260
| | - B Scavino
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - C Schwanda
- Institute of High Energy Physics, Vienna 1050
| | - A J Schwartz
- University of Cincinnati, Cincinnati, Ohio 45221
| | - R M Seddon
- McGill University, Montréal, Québec, H3A 2T8
| | - Y Seino
- Niigata University, Niigata 950-2181
| | - A Selce
- INFN Sezione di Roma, I-00185 Roma
- Università di Roma "La Sapienza," I-00185 Roma
| | - K Senyo
- Yamagata University, Yamagata 990-8560
| | - J Serrano
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | - M E Sevior
- School of Physics, University of Melbourne, Victoria 3010
| | - C Sfienti
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - J-G Shiu
- Department of Physics, National Taiwan University, Taipei 10617
| | - A Sibidanov
- University of Victoria, Victoria, British Columbia V8W 3P6
| | - F Simon
- Max-Planck-Institut für Physik, 80805 München
| | - R J Sobie
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of Victoria, Victoria, British Columbia V8W 3P6
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv 69978
| | - E Solovieva
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - S Spataro
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - B Spruck
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - M Starič
- J. Stefan Institute, 1000 Ljubljana
| | - S Stefkova
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - Z S Stottler
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova
| | - J Strube
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - M Sumihama
- Gifu University, Gifu 501-1193
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - T Sumiyoshi
- Tokyo Metropolitan University, Tokyo 192-0397
| | - D J Summers
- University of Mississippi, University, Mississippi 38677
| | | | - H Svidras
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - M Tabata
- Chiba University, Chiba 263-8522
| | - M Takizawa
- J-PARC Branch, KEK Theory Center, High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Theoretical Research Division, Nishina Center, RIKEN, Saitama 351-0198
- Showa Pharmaceutical University, Tokyo 194-8543
| | - U Tamponi
- INFN Sezione di Torino, I-10125 Torino
| | - S Tanaka
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - K Tanida
- Advanced Science Research Center, Japan Atomic Energy Agency, Naka 319-1195
| | - H Tanigawa
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec H3C 3J7
| | - F Tenchini
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - D Tonelli
- INFN Sezione di Trieste, I-34127 Trieste
| | - E Torassa
- INFN Sezione di Padova, I-35131 Padova
| | - K Trabelsi
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - M Uchida
- Tokyo Institute of Technology, Tokyo 152-8550
| | - T Uglov
- Higher School of Economics (HSE), Moscow 101000
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - K Unger
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - Y Unno
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - S Uno
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Urquijo
- School of Physics, University of Melbourne, Victoria 3010
| | - Y Ushiroda
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - S E Vahsen
- University of Hawaii, Honolulu, Hawaii 96822
| | | | - G S Varner
- University of Hawaii, Honolulu, Hawaii 96822
| | - K E Varvell
- School of Physics, University of Sydney, New South Wales 2006
| | - A Vinokurova
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - L Vitale
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - E Waheed
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Wakai
- University of British Columbia, Vancouver, British Columbia V6T 1Z1
| | | | - C H Wang
- National United University, Miao Li 36003
| | - M-Z Wang
- Department of Physics, National Taiwan University, Taipei 10617
| | - X L Wang
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - A Warburton
- McGill University, Montréal, Québec, H3A 2T8
| | | | - S Watanuki
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay
| | - J Webb
- School of Physics, University of Melbourne, Victoria 3010
| | - S Wehle
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | | | | | - H Windel
- Max-Planck-Institut für Physik, 80805 München
| | - E Won
- Korea University, Seoul 02841
| | - L J Wu
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - X P Xu
- Soochow University, Suzhou 215006
| | - B Yabsley
- School of Physics, University of Sydney, New South Wales 2006
| | - W Yan
- University of Science and Technology of China, Hefei 230026
| | | | - H Ye
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - M Yonenaga
- Tokyo Metropolitan University, Tokyo 192-0397
| | - C Z Yuan
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - Y Yusa
- Niigata University, Niigata 950-2181
| | - L Zani
- Aix Marseille Université, CNRS/IN2P3, CPPM, 13288 Marseille
| | - Q D Zhou
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - V I Zhukova
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| |
Collapse
|
28
|
Curtis JR, Weinblatt M, Saag K, Bykerk VP, Furst DE, Fiore S, St John G, Kimura T, Zheng S, Bingham CO, Wright G, Bergman M, Nola K, Charles-Schoeman C, Shadick N. Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. Arthritis Care Res (Hoboken) 2020; 73:471-480. [PMID: 33002337 PMCID: PMC8048846 DOI: 10.1002/acr.24471] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Accepted: 09/24/2020] [Indexed: 12/30/2022]
Abstract
Objective To use unbiased, data‐driven, principal component (PC) and cluster analysis to identify patient phenotypes of rheumatoid arthritis (RA) that might exhibit distinct trajectories of disease progression, response to treatment, and risk for adverse events. Methods Patient demographic, socioeconomic, health, and disease characteristics recorded at entry into a large, single‐center, prospective observational registry cohort, the Brigham and Women’s Rheumatoid Arthritis Sequential Study (BRASS), were harmonized using PC analysis to reduce dimensionality and collinearity. The number of PCs was established by eigenvalue >1, cumulative variance, and interpretability. The resulting PCs were used to cluster patients using a K‐means approach. Longitudinal clinical outcomes were compared between the clusters over 2 years. Results Analysis of 142 variables from 1,443 patients identified 41 PCs that accounted for 77% of the cumulative variance in the data set. Cluster analysis distinguished 5 patient clusters: 1) less RA disease activity/multimorbidity, shorter RA duration, lower incidence of comorbidities; 2) less RA disease activity/multimorbidity, longer RA duration, more infections, psychiatric comorbidities, health care utilization; 3) moderate RA disease activity/multimorbidity, more neurologic comorbidity; 4) more RA disease activity/multimorbidity, shorter RA duration, more metabolic comorbidity, higher body mass index; 5) more RA disease activity/multimorbidity, longer RA duration, more hepatic, orthopedic comorbidity and RA‐related surgeries. The clusters exhibited differences in clinical outcomes over 2 years of follow‐up. Conclusion Data‐driven analysis of the BRASS registry identified 5 distinct phenotypes of RA. These results illustrate the potential of data‐driven patient profiling as a tool to support personalized medicine in RA. Validation in an independent data set is ongoing.
Collapse
Affiliation(s)
| | | | | | | | - Daniel E Furst
- University of California, Los Angeles, University of Washington, Seattle, and University of Florence, Florence, Italy
| | | | | | | | | | | | | | - Martin Bergman
- Drexel University College of Medicine, Philadelphia, Pennsylvania
| | - Kamala Nola
- Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee
| | | | | |
Collapse
|
29
|
Andreoli F, Angelone M, Colangeli A, Besi Vetrella U, Fiore S, Flammini D, Del Prete P, Loreti S, Mariano G, Mazzitelli G, Moro F, Pagano G, Pietropaolo A, Pillon M, Terranova N, Villari R, Naish J, Nobs C, Packer L. Comparison between measurement and calculations for a 14 MeV neutron water activation experiment. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023921002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The nuclear heat loads due to gamma rays emitted from the decay of 16N and delayed neutrons from17N, generated by the activation of water in cooling circuits, are critical for ITER design. The assessment of nuclear heating from activated water is complex; it requires temporal and spatial dependent transport and activation calculations taking into account variation of irradiation, water flow conditions and cooling circuits’ parameters. A water activation experiment has been recently conducted at the14 MeV Frascati Neutron Generator (FNG) in order to validate the methodology for water activation assessment used for ITER and to reduce the safety factors applied to the calculation results, which have a large impact on the schedule, commissioning and licensing. Water circulating inside an ITER First Wall (FW) mock-up was irradiated with 14 MeV neutrons and then measured using a large CsI scintillator detector. The system consists of a closed water loop where the cooling water, transiting through an ITER FW mock-up, is irradiated by FNG. The induced 16N activity via 14 MeV neutrons interactions with 16O via the 16O(n,p)16N reaction is measured in a dedicated counting station via an expansion volume. The water then passes to a much larger holding delay tank, and after several 16N half-lives decay time, it is then recirculated and exposed again to neutrons in the ITER First Wall (FW) mock-up. The measured 16N activity is obtained measuring the emitted characteristic 6.13 and 7.12 MeV gamma-rays. Calculations were performed in an accurate model of the FW mock-up using the MCNP Monte Carlo code and FENDL-3.1 nuclear data library to obtain the predicted flux impinging on the water. The EASY-2007 inventory code was used to predict the 16N activity. In this work, a comparison between measurements and calculations is reported together with associated uncertainty analysis.
Collapse
|
30
|
Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis 2020; 80:96-102. [PMID: 32719038 PMCID: PMC7788059 DOI: 10.1136/annrheumdis-2020-217209] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Revised: 06/16/2020] [Accepted: 06/17/2020] [Indexed: 12/22/2022]
Abstract
Objectives This study evaluated the comparative effectiveness of a tumour necrosis factor inhibitor (TNFi) versus a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs)) as the first-line treatment following conventional synthetic DMARDs, as well as potential modifiers of response, observed in US clinical practice. Methods Data were from a large US healthcare registry (Consortium of Rheumatology Researchers of North America Rheumatoid Arthritis Registry). The analysis included patients (aged ≥18 years) with a documented diagnosis of rheumatoid arthritis (RA), a valid baseline Clinical Disease Activity Index (CDAI) score of >2.8 and no prior bDMARD or tsDMARD use. Outcomes were captured at 1-year postinitiation of a TNFi (adalimumab, etanercept, certolizumab pegol, golimumab or infliximab) or a non-TNFi (abatacept, tocilizumab, rituximab, anakinra or tofacitinib) and included CDAI, 28-Joint Modified Disease Activity Score, patient-reported outcomes (including the Health Assessment Questionnaire Disability Index, EuroQol-5 Dimension score, sleep, anxiety, morning stiffness and fatigue) and rates of anaemia. Groups were propensity score-matched at baseline to account for potential confounding. Results There were no statistically significant differences observed between the TNFi and non-TNFi treatment groups for outcomes assessed, except the incidence rate ratio for anaemia, which slightly favoured the TNFi group (19.04 per 100 person-years) versus the non-TNFi group (24.01 per 100 person-years, p=0.03). No potential effect modifiers were found to be statistically significant. Conclusions The findings of no significant differences in outcomes between first-line TNF versus first-line non-TNF groups support RA guidelines, which recommend individualised care based on clinical judgement and consideration of patient preferences.
Collapse
Affiliation(s)
- Dimitrios A Pappas
- Division of Rheumatology, Department of Medicine, Columbia University Medical Center, New York, New York, USA .,Corrona, LLC, Waltham, Massachusetts, USA
| | | | | | | | | | - Toshio Kimura
- Medical Analytics, Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA
| | | | | | | | - Susan Boklage
- Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA
| | - Joel M Kremer
- Corrona, LLC, Waltham, Massachusetts, USA.,Albany Medical College, Albany, New York, USA
| |
Collapse
|
31
|
Burmester GR, Morello JP, Hagino O, Praestgaard A, Fiore S, Genovese MC. SAT0100 ASSOCIATION BETWEEN LOW HEMOGLOBIN AND RADIOGRAPHIC PROGRESSION OVER 52 WEEKS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL OF SARILUMAB. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Anemia is a common comorbidity in patients with rheumatoid arthritis (RA).Objectives:Assess whether low hemoglobin (Hb) identifies a subgroup of patients at increased risk of joint damage progression, and investigate whether sarilumab modulates this risk.Methods:The 52-week, double-blind, Phase 3 MOBILITY trial (NCT01061736) in patients with active RA and inadequate response to methotrexate (n = 1197) demonstrated the tolerability and efficacy (clinical and radiographic) of subcutaneous sarilumab 150 and 200 mg every 2 weeks versus placebo, both in combination with methotrexate (MTX). In thispost hocanalysis, baseline characteristics and radiographic outcomes in MOBILITY were analyzed by baseline Hb category (low or normal) according to World Health Organization criteria, with low Hb defined as <120 g/L for women and <130 g/L for men. NominalPvalues are presented.Results:A total of 414 patients (35%) had low Hb at baseline. Patients with low Hb were more likely than patients with normal Hb to be female (86% vs 79%, respectively), Asian (14% vs 5%), younger (mean age 49 vs 51 years), and to have lower body weight (mean 69 vs 77 kg); all nominalP<0.01. Duration of RA, prior biologic use, rheumatoid factor positivity, and baseline tender and swollen joint counts were similar between patients with low and normal baseline Hb, but there was a nominally significant difference in C-reactive protein (mean 30.2 [SD 28.5] vs 17.3 [18.5] mg/L;P<0.0001). Patients with low Hb generally exhibited more joint damage progression over 52 weeks than patients with normal Hb (Table). In the sarilumab + MTX groups, joint damage progression was mitigated compared with placebo + MTX in patients with low Hb and in patients with normal Hb. Mean change from baseline in Hb at 52 weeks in the placebo + MTX, sarilumab 150 mg + MTX, and sarilumab 200 mg + MTX groups was +3.7 (SD 10.8), +14.7 (12.1), and +14.0 (10.5) g/L, respectively, in patients with low Hb at baseline, and –2.5 (9.9), +6.2 (9.3), and +8.0 (9.9) g/L in patients with normal Hb at baseline.Table.Mean change from baseline (SD) in radiographic measures of joint damagePlacebo+ MTXSarilumab 150 mg+ MTXSarilumab 200 mg+ MTXLow Hb (n = 140)Normal Hb (n = 258)Low Hb (n = 145)Normal Hb (n = 255)Low Hb (n = 129)Normal Hb (n = 270)mTSS3.75 (9.00)2.29 (6.98)1.20*** (5.58)0.73** (4.07)0.60*** (4.13)0.08*** (4.83)Joint space narrowing1.52 (3.71)1.22 (3.92)0.79* (3.17)0.30** (2.70)0.50** (2.93)0.06*** (3.33)Erosion score2.24 (6.24)1.07 (3.91)0.41*** (3.18)0.44* (2.05)0.10*** (2.13)0.02*** (2.19)NominalP*<0.05, **<0.01, ***<0.001 versus placebo by rank ANCOVA model stratified by prior biologic use and region; mTSS, modified total Sharp scoreConclusion:Overall, sarilumab slowed joint damage progression in patients with RA. Additionally, in those patients with low Hb, who may suffer greater damage than those with normal Hb, sarilumab also increased Hb.Acknowledgments:Study funding and medical writing support (Matt Lewis, PhD, of Adelphi Communications Ltd, Macclesfield, UK) were provided by Sanofi Genzyme (Cambridge, MA, USA) and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA) in accordance with Good Publication Practice (GPP3) guidelines.Disclosure of Interests:Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Jean-Pierre Morello Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., Owen Hagino Shareholder of: Sanofi, Employee of: Sanofi, Amy Praestgaard Employee of: Sanofi Genzyme, Stefano Fiore Shareholder of: Sanofi, Employee of: Sanofi, Mark C. Genovese Grant/research support from: Abbvie, Eli Lilly and Company, EMD Merck Serono, Galapagos, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, Pfizer Inc., RPharm, Sanofi Genzyme, Consultant of: Abbvie, Eli Lilly and Company, EMD Merck Serono, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, RPharm, Sanofi Genzyme
Collapse
|
32
|
Stefanelli P, Faggioni G, Lo Presti A, Fiore S, Marchi A, Benedetti E, Fabiani C, Anselmo A, Ciammaruconi A, Fortunato A, De Santis R, Fillo S, Capobianchi MR, Gismondo MR, Ciervo A, Rezza G, Castrucci MR, Lista F, On Behalf Of Iss Covid-Study Group. Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe. ACTA ACUST UNITED AC 2020; 25. [PMID: 32265007 PMCID: PMC7140597 DOI: 10.2807/1560-7917.es.2020.25.13.2000305] [Citation(s) in RCA: 113] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Whole genome sequences of SARS-CoV-2 obtained from two patients, a Chinese tourist visiting Rome and an Italian, were compared with sequences from Europe and elsewhere. In a phylogenetic tree, the Italian patient’s sequence clustered with sequences from Germany while the tourist’s sequence clustered with other European sequences. Some additional European sequences in the tree segregated outside the two clusters containing the patients’ sequences. This suggests multiple SARS-CoV-2 introductions in Europe or virus evolution during circulation.
Collapse
Affiliation(s)
- Paola Stefanelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | | | | | - Stefano Fiore
- These authors contributed equally to the work.,Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Antonella Marchi
- These authors contributed equally to the work.,Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Eleonora Benedetti
- These authors contributed equally to the work.,Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Concetta Fabiani
- These authors contributed equally to the work.,Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Anna Anselmo
- Scientific Department Army Medical Center, Rome, Italy
| | | | | | | | - Silvia Fillo
- Scientific Department Army Medical Center, Rome, Italy
| | - Maria Rosaria Capobianchi
- Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy
| | - Maria Rita Gismondo
- Clinical Microbiology, Virology and Bioemergency, L. Sacco University Hospital, Milan, Italy
| | - Alessandra Ciervo
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Giovanni Rezza
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | | | | | | |
Collapse
|
33
|
Adachi I, Ahlburg P, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Aziz T, Babu V, Baehr S, Bambade P, Banerjee S, Bansal V, Barrett M, Baudot J, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertemes M, Bessner M, Bettarini S, Bianchi F, Biswas D, Bozek A, Bračko M, Branchini P, Briere RA, Browder TE, Budano A, Burmistrov L, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Červenkov D, Chang MC, Cheaib R, Chekelian V, Chen YQ, Chen YT, Cheon BG, Chilikin K, Cho K, Cho S, Choi SK, Choudhury S, Cinabro D, Corona L, Cremaldi LM, Cunliffe S, Czank T, Dattola F, De La Cruz-Burelo E, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Di Capua F, Doležal Z, Domínguez Jiménez I, Dong TV, Dort K, Dossett D, Dubey S, Duell S, Dujany G, Eidelman S, Eliachevitch M, Fast JE, Ferber T, Ferlewicz D, Finocchiaro G, Fiore S, Fodor A, Forti F, Fulsom BG, Ganiev E, Garcia-Hernandez M, Garg R, Gaur V, Gaz A, Gellrich A, Gemmler J, Geßler T, Giordano R, Giri A, Gobbo B, Godang R, Goldenzweig P, Golob B, Gomis P, Gradl W, Graziani E, Greenwald D, Guan Y, Hadjivasiliou C, Halder S, Hara T, Hartbrich O, Hayasaka K, Hayashii H, Hearty C, Hedges MT, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hoek M, Hsu CL, Hu Y, Iijima T, Inami K, Inguglia G, Irakkathil Jabbar J, Ishikawa A, Itoh R, Iwasaki Y, Jacobs WW, Jaffe DE, Jang EJ, Jeon HB, Jia S, Jin Y, Joo C, Joo KK, Kahn J, Kakuno H, Kaliyar AB, Kandra J, Karyan G, Kato Y, Kawasaki T, Kim BH, Kim CH, Kim DY, Kim KH, Kim SH, Kim YK, Kim Y, Kimmel TD, Kindo H, Kleinwort C, Kodyš P, Koga T, Kohani S, Komarov I, Korpar S, Kovalchuk N, Kraetzschmar TMG, Križan P, Kroeger R, Krokovny P, Kuhr T, Kumar J, Kumar M, Kumar R, Kumara K, Kurz S, Kuzmin A, Kwon YJ, Lacaprara S, La Licata C, Lanceri L, Lange JS, Lautenbach K, Lee IS, Lee SC, Leitl P, Levit D, Li LK, Li YB, Libby J, Lieret K, Li Gioi L, Liptak Z, Liu QY, Liventsev D, Longo S, Luo T, Maeda Y, Maggiora M, Manoni E, Marcello S, Marinas C, Martini A, Masuda M, Matsuda T, Matsuoka K, Matvienko D, Meggendorfer F, Mei JC, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Miyake H, Mizuk R, Azmi K, Mohanty GB, Moon T, Morii T, Moser HG, Mueller F, Müller FJ, Muller T, Muroyama G, Mussa R, Nakano E, Nakao M, Nayak M, Nazaryan G, Neverov D, Niebuhr C, Nisar NK, Nishida S, Nishimura K, Nishimura M, Oberhof B, Ogawa K, Onishchuk Y, Ono H, Onuki Y, Oskin P, Ozaki H, Pakhlov P, Pakhlova G, Paladino A, Panta A, Paoloni E, Park H, Paschen B, Passeri A, Pathak A, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Piccolo M, Piilonen LE, Popov V, Praz C, Prencipe E, Prim MT, Purohit MV, Rados P, Rasheed R, Reiter S, Remnev M, Resmi PK, Ripp-Baudot I, Ritter M, Rizzo G, Rizzuto LB, Robertson SH, Rodríguez Pérez D, Roney JM, Rosenfeld C, Rostomyan A, Rout N, Russo G, Sahoo D, Sakai Y, Sandilya S, Sangal A, Santelj L, Sartori P, Sato Y, Savinov V, Scavino B, Schueler J, Schwanda C, Seddon RM, Seino Y, Selce A, Senyo K, Sfienti C, Shen CP, Shiu JG, Shwartz B, Sibidanov A, Simon F, Sobie RJ, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Strube J, Sumihama M, Sumiyoshi T, Summers DJ, Suzuki SY, Tabata M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Taniguchi N, Taras P, Tenchini F, Torassa E, Trabelsi K, Tsuboyama T, Uchida M, Unger K, Unno Y, Uno S, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Vossen A, Wakai M, Wakeling HM, Wan Abdullah W, Wang CH, Wang MZ, Warburton A, Watanabe M, Webb J, Wehle S, Wessel C, Wiechczynski J, Windel H, Won E, Yabsley B, Yamada S, Yan W, Yang SB, Ye H, Yin JH, Yonenaga M, Yuan CZ, Yusa Y, Zani L, Zhang Z, Zhilich V, Zhou QD, Zhou XY, Zhukova VI. Search for an Invisibly Decaying Z^{'} Boson at Belle II in e^{+}e^{-}→μ^{+}μ^{-}(e^{±}μ^{∓}) Plus Missing Energy Final States. Phys Rev Lett 2020; 124:141801. [PMID: 32338980 DOI: 10.1103/physrevlett.124.141801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Accepted: 02/24/2020] [Indexed: 06/11/2023]
Abstract
Theories beyond the standard model often predict the existence of an additional neutral boson, the Z^{'}. Using data collected by the Belle II experiment during 2018 at the SuperKEKB collider, we perform the first searches for the invisible decay of a Z^{'} in the process e^{+}e^{-}→μ^{+}μ^{-}Z^{'} and of a lepton-flavor-violating Z^{'} in e^{+}e^{-}→e^{±}μ^{∓}Z^{'}. We do not find any excess of events and set 90% credibility level upper limits on the cross sections of these processes. We translate the former, in the framework of an L_{μ}-L_{τ} theory, into upper limits on the Z^{'} coupling constant at the level of 5×10^{-2}-1 for M_{Z^{'}}≤6 GeV/c^{2}.
Collapse
Affiliation(s)
- I Adachi
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | | | - H Aihara
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - N Akopov
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - A Aloisio
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - N Anh Ky
- Institute of Theoretical and Applied Research (ITAR), Duy Tan University, Hanoi 100000, Vietnam
- Institute of Physics, Hanoi
| | - D M Asner
- Brookhaven National Laboratory, Upton, New York 11973
| | - H Atmacan
- University of Cincinnati, Cincinnati, Ohio 45221
| | - T Aushev
- Moscow Institute of Physics and Technology, Moscow Region 141700
| | - V Aushev
- Taras Shevchenko National Univ. of Kiev, Kiev
| | - T Aziz
- Tata Institute of Fundamental Research, Mumbai 400005
| | - V Babu
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Baehr
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - P Bambade
- Laboratoire de l'Accélérateur Linéaire, IN2P3/CNRS et Université Paris-Sud 11, Centre Scientifique d'Orsay, F-91898 Orsay Cedex
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292
| | - V Bansal
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - M Barrett
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - J Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - J Becker
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - P K Behera
- Indian Institute of Technology Madras, Chennai 600036
| | - J V Bennett
- University of Mississippi, University, Mississippi 38677
| | | | | | - M Bertemes
- Institute of High Energy Physics, Vienna 1050, Austria
| | - M Bessner
- University of Hawaii, Honolulu, Hawaii 96822
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - D Biswas
- University of Louisville, Louisville, Kentucky 40292
| | - A Bozek
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342
| | - M Bračko
- J. Stefan Institute, 1000 Ljubljana
- University of Maribor, 2000 Maribor
| | | | - R A Briere
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213
| | - T E Browder
- University of Hawaii, Honolulu, Hawaii 96822
| | - A Budano
- INFN Sezione di Roma Tre, I-00146 Roma
| | - L Burmistrov
- Laboratoire de l'Accélérateur Linéaire, IN2P3/CNRS et Université Paris-Sud 11, Centre Scientifique d'Orsay, F-91898 Orsay Cedex
| | - S Bussino
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - M Campajola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - L Cao
- University of Bonn, 53115 Bonn
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - C Cecchi
- INFN Sezione di Perugia, I-06123 Perugia
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia
| | - D Červenkov
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - M-C Chang
- Department of Physics, Fu Jen Catholic University, Taipei 24205
| | - R Cheaib
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - V Chekelian
- Max-Planck-Institut für Physik, 80805 München
| | - Y Q Chen
- University of Science and Technology of China, Hefei 230026
| | - Y-T Chen
- Department of Physics, National Taiwan University, Taipei 10617
| | - B G Cheon
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - K Chilikin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - K Cho
- Korea Institute of Science and Technology Information, Daejeon 34141
| | - S Cho
- Yonsei University, Seoul 03722
| | - S-K Choi
- Gyeongsang National University, Jinju 52828
| | - S Choudhury
- Indian Institute of Technology Hyderabad, Telangana 502285
| | - D Cinabro
- Wayne State University, Detroit, Michigan 48202
| | - L Corona
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - L M Cremaldi
- University of Mississippi, University, Mississippi 38677
| | - S Cunliffe
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - T Czank
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - F Dattola
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - E De La Cruz-Burelo
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - G De Nardo
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - M De Nuccio
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - G De Pietro
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - M Destefanis
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - S Dey
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv, 69978
| | - A De Yta-Hernandez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - F Di Capua
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - Z Doležal
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | | | - T V Dong
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - K Dort
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - D Dossett
- School of Physics, University of Melbourne, Victoria 3010
| | - S Dubey
- University of Hawaii, Honolulu, Hawaii 96822
| | - S Duell
- University of Bonn, 53115 Bonn
| | - G Dujany
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - S Eidelman
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | | | - J E Fast
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - T Ferber
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - D Ferlewicz
- School of Physics, University of Melbourne, Victoria 3010
| | - G Finocchiaro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - S Fiore
- INFN Sezione di Roma, I-00185 Roma
| | - A Fodor
- McGill University, Montréal, Québec, H3A 2T8
| | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - B G Fulsom
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - E Ganiev
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - M Garcia-Hernandez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - R Garg
- Panjab University, Chandigarh 160014
| | - V Gaur
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - A Gaz
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - A Gellrich
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - J Gemmler
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - T Geßler
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - R Giordano
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - A Giri
- Indian Institute of Technology Hyderabad, Telangana 502285
| | - B Gobbo
- INFN Sezione di Trieste, I-34127 Trieste
| | - R Godang
- University of South Alabama, Mobile, Alabama 36688
| | - P Goldenzweig
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - B Golob
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Gomis
- Instituto de Fisica Corpuscular, Paterna 46980
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | | | - D Greenwald
- Department of Physics, Technische Universität München, 85748 Garching
| | - Y Guan
- University of Cincinnati, Cincinnati, Ohio 45221
| | - C Hadjivasiliou
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - S Halder
- Tata Institute of Fundamental Research, Mumbai 400005
| | - T Hara
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - O Hartbrich
- University of Hawaii, Honolulu, Hawaii 96822
| | | | | | - C Hearty
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - M T Hedges
- University of Hawaii, Honolulu, Hawaii 96822
| | - I Heredia de la Cruz
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
- Consejo Nacional de Ciencia y Tecnología, Mexico City 03940
| | | | - A Hershenhorn
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - T Higuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - E C Hill
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - M Hoek
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - C-L Hsu
- School of Physics, University of Sydney, New South Wales 2006
| | - Y Hu
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - T Iijima
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - K Inami
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - G Inguglia
- Institute of High Energy Physics, Vienna 1050, Austria
| | - J Irakkathil Jabbar
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - A Ishikawa
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - R Itoh
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - Y Iwasaki
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973
| | - E-J Jang
- Gyeongsang National University, Jinju 52828
| | - H B Jeon
- Kyungpook National University, Daegu 41566
| | - S Jia
- Beihang University, Beijing 100191
| | - Y Jin
- INFN Sezione di Trieste, I-34127 Trieste
| | - C Joo
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - K K Joo
- Chonnam National University, Gwangju 61186
| | - J Kahn
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - H Kakuno
- Tokyo Metropolitan University, Tokyo 192-0397
| | - A B Kaliyar
- Tata Institute of Fundamental Research, Mumbai 400005
| | - J Kandra
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - G Karyan
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - Y Kato
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - T Kawasaki
- Kitasato University, Sagamihara 252-0373
| | - B H Kim
- Seoul National University, Seoul 08826
| | - C-H Kim
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - D Y Kim
- Soongsil University, Seoul 06978
| | - K-H Kim
- Yonsei University, Seoul 03722
| | - S-H Kim
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - Y K Kim
- Yonsei University, Seoul 03722
| | - Y Kim
- Korea University, Seoul 02841
| | - T D Kimmel
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - H Kindo
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - C Kleinwort
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - P Kodyš
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - T Koga
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - S Kohani
- University of Hawaii, Honolulu, Hawaii 96822
| | - I Komarov
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Korpar
- J. Stefan Institute, 1000 Ljubljana
- University of Maribor, 2000 Maribor
| | - N Kovalchuk
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | - P Križan
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - R Kroeger
- University of Mississippi, University, Mississippi 38677
| | - P Krokovny
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - T Kuhr
- Ludwig Maximilians University, 80539 Munich
| | - J Kumar
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213
| | - M Kumar
- Malaviya National Institute of Technology Jaipur, Jaipur 302017
| | - R Kumar
- Punjab Agricultural University, Ludhiana 141004
| | - K Kumara
- Wayne State University, Detroit, Michigan 48202
| | - S Kurz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - A Kuzmin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | | | | | - C La Licata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - L Lanceri
- INFN Sezione di Trieste, I-34127 Trieste
| | - J S Lange
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | | | - I-S Lee
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - S C Lee
- Kyungpook National University, Daegu 41566
| | - P Leitl
- Max-Planck-Institut für Physik, 80805 München
| | - D Levit
- Department of Physics, Technische Universität München, 85748 Garching
| | - L K Li
- University of Cincinnati, Cincinnati, Ohio 45221
| | - Y B Li
- Peking University, Beijing 100871
| | - J Libby
- Indian Institute of Technology Madras, Chennai 600036
| | - K Lieret
- Ludwig Maximilians University, 80539 Munich
| | - L Li Gioi
- Max-Planck-Institut für Physik, 80805 München
| | - Z Liptak
- University of Hawaii, Honolulu, Hawaii 96822
| | - Q Y Liu
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - D Liventsev
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - S Longo
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - T Luo
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - Y Maeda
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - M Maggiora
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia
| | - S Marcello
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - C Marinas
- Instituto de Fisica Corpuscular, Paterna 46980
| | - A Martini
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - M Masuda
- Earthquake Research Institute, University of Tokyo, Tokyo 113-0032
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - T Matsuda
- University of Miyazaki, Miyazaki 889-2192
| | - K Matsuoka
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - D Matvienko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | | | - J C Mei
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - F Meier
- Duke University, Durham, North Carolina 27708
| | - M Merola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - F Metzner
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - M Milesi
- School of Physics, University of Melbourne, Victoria 3010
| | - C Miller
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | | | - H Miyake
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - R Mizuk
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - K Azmi
- National Centre for Particle Physics, University Malaya, 50603 Kuala Lumpur
| | - G B Mohanty
- Tata Institute of Fundamental Research, Mumbai 400005
| | - T Moon
- Seoul National University, Seoul 08826
| | - T Morii
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - H-G Moser
- Max-Planck-Institut für Physik, 80805 München
| | - F Mueller
- Max-Planck-Institut für Physik, 80805 München
| | - F J Müller
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - Th Muller
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - G Muroyama
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - R Mussa
- INFN Sezione di Torino, I-10125 Torino
| | - E Nakano
- Osaka City University, Osaka 558-8585
| | - M Nakao
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Nayak
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv, 69978
| | - G Nazaryan
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - D Neverov
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - C Niebuhr
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N K Nisar
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260
| | - S Nishida
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - K Nishimura
- University of Hawaii, Honolulu, Hawaii 96822
| | - M Nishimura
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - B Oberhof
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - K Ogawa
- Niigata University, Niigata 950-2181
| | - Y Onishchuk
- Taras Shevchenko National Univ. of Kiev, Kiev
| | - H Ono
- Niigata University, Niigata 950-2181
| | - Y Onuki
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - P Oskin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - H Ozaki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Pakhlov
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Moscow Physical Engineering Institute, Moscow 115409
| | - G Pakhlova
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Moscow Institute of Physics and Technology, Moscow Region 141700
| | - A Paladino
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - A Panta
- University of Mississippi, University, Mississippi 38677
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - H Park
- Kyungpook National University, Daegu 41566
| | | | - A Passeri
- INFN Sezione di Roma Tre, I-00146 Roma
| | - A Pathak
- University of Louisville, Louisville, Kentucky 40292
| | - S Paul
- Department of Physics, Technische Universität München, 85748 Garching
| | | | - I Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - R Peschke
- University of Hawaii, Honolulu, Hawaii 96822
| | | | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - L E Piilonen
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - V Popov
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Moscow Institute of Physics and Technology, Moscow Region 141700
| | - C Praz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | - M T Prim
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - M V Purohit
- Okinawa Institute of Science and Technology, Okinawa 904-0495
| | - P Rados
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - R Rasheed
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - S Reiter
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - M Remnev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - P K Resmi
- Indian Institute of Technology Madras, Chennai 600036
| | - I Ripp-Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - M Ritter
- Ludwig Maximilians University, 80539 Munich
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | | | - S H Robertson
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- McGill University, Montréal, Québec, H3A 2T8
| | | | - J M Roney
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - C Rosenfeld
- University of South Carolina, Columbia, South Carolina 29208
| | - A Rostomyan
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N Rout
- Indian Institute of Technology Madras, Chennai 600036
| | - G Russo
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - D Sahoo
- Tata Institute of Fundamental Research, Mumbai 400005
| | - Y Sakai
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - S Sandilya
- University of Cincinnati, Cincinnati, Ohio 45221
| | - A Sangal
- University of Cincinnati, Cincinnati, Ohio 45221
| | - L Santelj
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Sartori
- INFN Sezione di Padova, I-35131 Padova
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova
| | - Y Sato
- Department of Physics, Tohoku University, Sendai 980-8578
| | - V Savinov
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260
| | - B Scavino
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - J Schueler
- University of Hawaii, Honolulu, Hawaii 96822
| | - C Schwanda
- Institute of High Energy Physics, Vienna 1050, Austria
| | - R M Seddon
- McGill University, Montréal, Québec, H3A 2T8
| | - Y Seino
- Niigata University, Niigata 950-2181
| | - A Selce
- INFN Sezione di Perugia, I-06123 Perugia
| | - K Senyo
- Yamagata University, Yamagata 990-8560
| | - C Sfienti
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - C P Shen
- Beihang University, Beijing 100191
| | - J-G Shiu
- Department of Physics, National Taiwan University, Taipei 10617
| | - B Shwartz
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - A Sibidanov
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - F Simon
- Max-Planck-Institut für Physik, 80805 München
| | - R J Sobie
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv, 69978
| | - A Sokolov
- Institute for High Energy Physics, Protvino 142281
| | - E Solovieva
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - S Spataro
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - B Spruck
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - M Starič
- J. Stefan Institute, 1000 Ljubljana
| | - S Stefkova
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - Z S Stottler
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova
| | - J Strube
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - M Sumihama
- Gifu University, Gifu 501-1193
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - T Sumiyoshi
- Tokyo Metropolitan University, Tokyo 192-0397
| | - D J Summers
- University of Mississippi, University, Mississippi 38677
| | - S Y Suzuki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Tabata
- Chiba University, Chiba 263-8522
| | - M Takizawa
- J-PARC Branch, KEK Theory Center, High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Theoretical Research Division, Nishina Center, RIKEN, Saitama 351-0198
- Showa Pharmaceutical University, Tokyo 194-8543
| | - U Tamponi
- INFN Sezione di Torino, I-10125 Torino
| | - S Tanaka
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - K Tanida
- Advanced Science Research Center, Japan Atomic Energy Agency, Naka 319-1195
| | - N Taniguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec, H3C 3J7
| | - F Tenchini
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - E Torassa
- INFN Sezione di Padova, I-35131 Padova
| | - K Trabelsi
- Laboratoire de l'Accélérateur Linéaire, IN2P3/CNRS et Université Paris-Sud 11, Centre Scientifique d'Orsay, F-91898 Orsay Cedex
| | - T Tsuboyama
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Uchida
- Tokyo Institute of Technology, Tokyo 152-8550
| | - K Unger
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - Y Unno
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - S Uno
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - Y Ushiroda
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - S E Vahsen
- University of Hawaii, Honolulu, Hawaii 96822
| | | | - G S Varner
- University of Hawaii, Honolulu, Hawaii 96822
| | - K E Varvell
- School of Physics, University of Sydney, New South Wales 2006
| | - A Vinokurova
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - L Vitale
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - A Vossen
- Duke University, Durham, North Carolina 27708
| | - M Wakai
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | | | - W Wan Abdullah
- National Centre for Particle Physics, University Malaya, 50603 Kuala Lumpur
| | - C H Wang
- National United University, Miao Li 36003
| | - M-Z Wang
- Department of Physics, National Taiwan University, Taipei 10617
| | - A Warburton
- McGill University, Montréal, Québec, H3A 2T8
| | | | - J Webb
- School of Physics, University of Melbourne, Victoria 3010
| | - S Wehle
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | | | - H Windel
- Max-Planck-Institut für Physik, 80805 München
| | - E Won
- Korea University, Seoul 02841
| | - B Yabsley
- School of Physics, University of Sydney, New South Wales 2006
| | - S Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - W Yan
- University of Science and Technology of China, Hefei 230026
| | | | - H Ye
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - J H Yin
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - M Yonenaga
- Tokyo Metropolitan University, Tokyo 192-0397
| | - C Z Yuan
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - Y Yusa
- Niigata University, Niigata 950-2181
| | - L Zani
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - Z Zhang
- University of Science and Technology of China, Hefei 230026
| | - V Zhilich
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - Q D Zhou
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - X Y Zhou
- Beihang University, Beijing 100191
| | - V I Zhukova
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| |
Collapse
|
34
|
Bykerk V, Wei W, Boklage S, Kimura T, Fiore S, John GS. EP25 Impact of sarilumab on unacceptable pain and inflammation control in moderately-to-severely active rheumatoid arthritis (RA) patients in 3 Phase 3 studies. Rheumatology (Oxford) 2020. [DOI: 10.1093/rheumatology/keaa109.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
In RA patients, unacceptable pain (UP) may persist despite inflammation control (refractory pain [RP]). Sarilumab is indicated (either with methotrexate or as monotherapy if methotrexate is not tolerated/appropriate) for adults with moderately-to-severely active RA with an inadequate response or intolerance to ≥ 1 conventional synthetic disease-modifying antirheumatics (csDMARD). The recommended dose is 200 mg every 2 weeks (q2w) with dose reduction to 150 mg if required for management of laboratory abnormalities. Three randomised controlled trials (RCTs) of subcutaneous sarilumab 150 or 200 mg q2w vs comparators showed meaningful improvements in pain. This analysis assessed UP and RP in these trials.
Methods
RCTs evaluated sarilumab 150 and 200 mg q2w vs placebo (+csDMARDs: MOBILITY/NCT01061736 and TARGET/NCT01709578) and sarilumab 200 mg q2w vs adalimumab 40 mg q2w (MONARCH/NCT02332590). Post-hoc analyses calculated odds ratios (ORs) of UP (based on patient acceptable symptom state on a threshold of visual analog scale pain >40 mm [0-100]), RP (UP+C-reactive protein <10 mg/L), and RP-strict (RP + ≤1 swollen joint count [SJC]), and associations between pain and fatigue (FACIT-Fatigue) and disease activity (Health Assessment Questionnaire [HAQ], SJC and tender joint count [TJC]). P values are nominal.
Results
Across all three trials, sarilumab 150 and 200 mg q2w had lower odds of UP (p < 0.05; ORs 0.39-0.46 vs placebo and 0.54 vs adalimumab). In MOBILITY, sarilumab 150 and 200 mg q2w had lower odds (p < 0.05) of RP vs placebo at Week 24 (ORs 0.60 [0.38,0.93] and 0.57 [0.37,0.87]) and Week 52 (ORs 0.64 [0.37,1.02] and 0.62 [0.37,1.02]), and RP-strict at Week 52 (0.41 [0.19,0.90] and 0.35 [0.16,0.76]). In TARGET, sarilumab 150 mg q2w had lower odds (p < 0.05) of RP-strict at Week 24. Higher pain was associated with worse FACIT-fatigue, HAQ, SJC and TJC scores (all p < 0.001).
Conclusion
Sarilumab was associated with lower odds of UP or RP vs adalimumab or placebo.
Disclosures
V. Bykerk: Consultancies; Abbvie, Amgen, Brainstorm Therapeutics, Bristol-Myers Squibb, Genentech, Gilead, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Scipher, Union Chimique Belge. Shareholder/stock ownership; Abbvie, Amgen, Brainstorm Therapeutics, Bristol-Myers Squibb, Genentech, Gilead, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Scipher, Union Chimique Belge. Grants/research support; AbbVie, Amgen, Brainstorm Therapeutics, Bristol-Myers Squibb, Genentech, Gilead, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Scipher, Union Chimique Belge. W. Wei: Shareholder/stock ownership; Regeneron Pharmaceuticals, Inc. Other; Regeneron Pharmaceuticals, Inc. S. Boklage: Shareholder/stock ownership; Regeneron Pharmaceuticals, Inc. Other; Regeneron Pharmaceuticals, Inc. T. Kimura: Shareholder/stock ownership; Regeneron Pharmaceuticals, Inc. Other; Regeneron Pharmaceuticals, Inc. S. Fiore: Shareholder/stock ownership; Sanofi. Other; Sanofi. G. St John: Shareholder/stock ownership; Regeneron Pharmaceuticals, Inc. Other; Regeneron Pharmaceuticals, Inc.
Collapse
Affiliation(s)
- Vivian Bykerk
- Inflammatory Arthritis, Hospital for Special Surgery, New York, NY, USA
| | - Wenhui Wei
- Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
| | - Susan Boklage
- Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
| | - Toshio Kimura
- Medical Analytics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
| | | | - Gregory St John
- Immunology and Inflammation, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
| |
Collapse
|
35
|
Fiore S, Aberle O, Angelone M, Calviani M, Di Giambattista F, Lepore L, Nyman M, Pillon M, Plompen A. Self Powered Neutron Detectors with High Energy Sensitivity. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202022502001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Fontana S, Fiore S, Buttinelli G, Amato C, Veronesi L, Zoni R, Triassi M, Pennino F, Giammanco GM, De Grazia S, Cicala A, Siragusa A, Gamper S, Spertini S, Castiglia P, Cossu A, Germinario C, Larocca AMV, Stefanelli P. Molecular Characterization of Coxsackievirus B5 Isolates from Sewage, Italy 2016-2017. Food Environ Virol 2019; 11:440-445. [PMID: 31346976 PMCID: PMC6848032 DOI: 10.1007/s12560-019-09395-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 07/19/2019] [Indexed: 06/10/2023]
Abstract
Hereby, the partial Viral Protein 1 sequences of Coxsackievirus B5 (CV-B5) from sewage samples, collected in Italy from 2016 to 2017, were compared with those available in GenBank from clinical samples. Phylogenetic analysis highlighted: (I) the predominant circulation of CV-B5 genogroup B in Italy, and (II) the presence of two new sub-genogroups.
Collapse
Affiliation(s)
- Stefano Fontana
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), Viale Regina Elena 299, 00161, Rome, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), Viale Regina Elena 299, 00161, Rome, Italy
| | - Gabriele Buttinelli
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), Viale Regina Elena 299, 00161, Rome, Italy
| | - Concetta Amato
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), Viale Regina Elena 299, 00161, Rome, Italy
| | - Licia Veronesi
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Roberta Zoni
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Maria Triassi
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Francesca Pennino
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Giovanni Maurizio Giammanco
- Department of Health Promotion, Mother and Child Care and Internal Medicine 'G. D'Alessandro', University of Palermo, Palermo, Italy
| | - Simona De Grazia
- Department of Health Promotion, Mother and Child Care and Internal Medicine 'G. D'Alessandro', University of Palermo, Palermo, Italy
| | | | | | - Sabine Gamper
- Comprensorio Sanitario di Bolzano, Servizio Igiene e Sanità Pubblica, Bolzano, Italy
| | - Silvia Spertini
- Comprensorio Sanitario di Bolzano, Servizio Igiene e Sanità Pubblica, Bolzano, Italy
| | - Paolo Castiglia
- Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
| | - Andrea Cossu
- Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
| | - Cinzia Germinario
- Department of Biomedical Science and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
| | | | - Paola Stefanelli
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), Viale Regina Elena 299, 00161, Rome, Italy.
| |
Collapse
|
37
|
Stefanelli P, Bellino S, Fiore S, Fontana S, Amato C, Buttinelli G. Hospital discharges-based search of acute flaccid paralysis cases 2007-2016 in Italy and comparison with the National Surveillance System for monitoring the risk of polio reintroduction. BMC Public Health 2019; 19:1532. [PMID: 31730455 PMCID: PMC6858761 DOI: 10.1186/s12889-019-7617-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Accepted: 09/12/2019] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Acute flaccid paralysis (AFP) surveillance has been adopted globally as a key strategy for monitoring the progress of the polio eradication initiative. Hereby, to evaluate the completeness of the ascertainment of AFP cases in Italy, a hospital-discharges based search was carried out. METHODS AFP cases occurring between 2007 and 2016 among children under 15 years of age were searched in the Italian Hospital Discharge Records (HDR) database using specific ICD-9-CM diagnostic codes. AFP cases identified between 2015 and 2016 were then compared with those notified to the National Surveillance System (NSS). RESULTS Over a 10-year period, 4163 hospital discharges with diagnosis of AFP were reported in Italy. Among these, 956 (23.0%) were acute infective polyneuritis, 1803 (43.3%) myopathy, and 1408 (33.8%) encephalitis, myelitis and encephalomyelitis. During the study period, a decreasing trend was observed for all diagnoses and overall the annual incidence rate (IR) declined from 5.5 to 4.5 per 100,000 children. Comparing NSS with HDR data in 2015-2016, we found a remarkable underreporting, being AFP cases from NSS only 14% of those recorded in HDR. In particular, the acute infective polyneuritis cases reported to NSS accounted for 42.6% of those detected in HDR, while only 0.9% of myopathy cases and 13.1% of encephalitis/myelitis/encephalomyelitis cases have been notified to NSS. The highest AFP IRs per 100,000 children calculated on HDR data were identified in Liguria (17.4), Sicily (5.7), and Veneto (5.1) Regions; regarding the AFP notified to the NSS, 11 out of 21 Regions failed to reach the number of expected cases (based on 1/100,000 rate), and the highest discrepancies were observed in the Northern Regions. Overall, the national AFP rate was equal to 0.6, therefore did not reach the target value. CONCLUSIONS AFP surveillance data are the final measure of a country's progress towards polio eradication. The historical data obtained by the HDR have been useful to assess the completeness of the notification data and to identify the Regions with a low AFP ascertainment rate in order to improve the national surveillance system.
Collapse
Affiliation(s)
- Paola Stefanelli
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità), Rome, Italy.
| | - Stefania Bellino
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità), Rome, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità), Rome, Italy
| | - Stefano Fontana
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità), Rome, Italy
| | - Concetta Amato
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità), Rome, Italy
| | - Gabriele Buttinelli
- Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità), Rome, Italy
| | | |
Collapse
|
38
|
Zoni R, Mezzetta S, Affanni P, Colucci ME, Fiore S, Fontana S, Bracchi M, Capobianco E, Veronesi L. Poliovirus and non-polio-enterovirus environmental surveillance in Parma within the "Global Polio Eradication Program" (GPEI). Acta Biomed 2019; 90:95-97. [PMID: 31517896 PMCID: PMC7233654 DOI: 10.23750/abm.v90i9-s.8702] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 07/23/2019] [Indexed: 12/04/2022]
Abstract
Poliovirus and non-polio-enterovirus environmental surveillance in Parma within the “Global Polio Eradication Program” (GPEI) Background: Environmental surveillance of poliovirus plays an essential role in GPEI both for the detection of WTP and VDPV circulation in endemic areas and for monitoring their absence in polio-free countries. Methods: Since 2005 to 2018, in Parma, 642 wastewater samples were collected from the two wastewater treatment plants and analyzed according to the WHO Guidelines. All isolates supposed being poliovirus were sent to ISS reference laboratory for molecular characterization while NPEV only refer to samples up to 2016. Results: Positivity was obtained in 68% of samples without significant difference between the two treatment plants. Six polioviruses (1.4%) were detected, all characterized as Sabin-like: 4 of them (66.7%) were type 3 and 2 (33.3%) type 1. Coxsackieviruses B mainly recurred among NPEV (85%) while residual 15% was Echoviruses. B4 was the most frequent Coxsackie serotype isolated (31%) while, among Echovirus, Echo 7 and Echo 11 prevail (both 23%). Conclusion: As OPV isn’t used in Italy since 2002, recovery of Sabin-like polioviruses indicates the possibility of poliovirus reintroduction, considering also the important exposure to migratory flows. Finally, monitoring the environmental circulation of NPEV, could compensate for the lack of a surveillance system of the infections they cause. (www.actabiomedica.it)
Collapse
Affiliation(s)
- Roberta Zoni
- Department of Medicine and Surgery - University of Parma.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Delogu R, Battistone A, Buttinelli G, Fiore S, Fontana S, Amato C, Cristiano K, Gamper S, Simeoni J, Frate R, Pellegrinelli L, Binda S, Veronesi L, Zoni R, Castiglia P, Cossu A, Triassi M, Pennino F, Germinario C, Balena V, Cicala A, Mercurio P, Fiore L, Pini C, Stefanelli P. Poliovirus and Other Enteroviruses from Environmental Surveillance in Italy, 2009-2015. Food Environ Virol 2018; 10:333-342. [PMID: 29948963 DOI: 10.1007/s12560-018-9350-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 06/08/2018] [Indexed: 06/08/2023]
Abstract
Within the initiatives for poliomyelitis eradication by WHO, Italy activated an environmental surveillance (ES) in 2005. ES complements clinical Acute Flaccid Paralysis (AFP) surveillance for possible polio cases, detects poliovirus circulation in environmental sewage, and is used to monitor transmission in communities. In addition to polioviruses, the analyses comprised: (i) the monitoring of the presence of non-polio enteroviruses in sewage samples and (ii) the temporal and geographical distribution of the detected viruses. From 2009 to 2015, 2880 sewage samples were collected from eight cities participating in the surveillance. Overall, 1479 samples resulted positive for enteroviruses. No wild-type polioviruses were found, although four Sabin-like polioviruses were detected. The low degree of mutation found in the genomes of these four isolates suggests that these viruses have had a limited circulation in the population. All non-polio enteroviruses belonged to species B and the most frequent serotype was CV-B5, followed by CV-B4, E-11, E-6, E-7, CV-B3, and CV-B2. Variations in the frequency of different serotypes were also observed in different seasons and/or Italian areas. Environmental surveillance in Italy, as part of the 'WHO global polio eradication program', is a powerful tool to augment the polio surveillance and to investigate the silent circulation or the re-emergence of enteroviruses in the population.
Collapse
Affiliation(s)
- Roberto Delogu
- National Centre for the Control and the Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy.
- National Centre for the Control and the Evaluation of Medicines, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161, Rome, Italy.
| | - Andrea Battistone
- National Centre for the Control and the Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy
| | - Gabriele Buttinelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fontana
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Concetta Amato
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Karen Cristiano
- National Centre for the Control and the Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy
| | - Sabine Gamper
- Comprensorio Sanitario di Bolzano, Servizio Igiene e Sanità Pubblica, Bolzano, Italy
| | - Josef Simeoni
- Comprensorio Sanitario di Bolzano, Servizio Igiene e Sanità Pubblica, Bolzano, Italy
| | | | - Laura Pellegrinelli
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| | - Sandro Binda
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| | - Licia Veronesi
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Roberta Zoni
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Paolo Castiglia
- Department of Biomedical Sciences, University of Sassari, Sassari, Italy
| | - Andrea Cossu
- Department of Biomedical Sciences, University of Sassari, Sassari, Italy
| | - Maria Triassi
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Francesca Pennino
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | | | - Viviana Balena
- Hygiene Unit, Department DIMO, University of Bari, Bari, Italy
| | | | | | - Lucia Fiore
- National Centre for the Control and the Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy
| | - Carlo Pini
- National Centre for the Control and the Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy
| | - Paola Stefanelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| |
Collapse
|
40
|
Pennino F, Nardone A, Montuori P, Aurino S, Torre I, Battistone A, Delogu R, Buttinelli G, Fiore S, Amato C, Triassi M. Large-Scale Survey of Human Enteroviruses in Wastewater Treatment Plants of a Metropolitan Area of Southern Italy. Food Environ Virol 2018; 10:187-192. [PMID: 29248990 DOI: 10.1007/s12560-017-9331-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Accepted: 12/07/2017] [Indexed: 05/21/2023]
Abstract
Human enteroviruses (HEVs) occur in high concentrations in wastewater and can contaminate receiving environmental waters, constituting a major cause of acute waterborne disease worldwide. In this study, we investigated the relative abundance, occurrence, and seasonal distribution of polio and other enteroviruses at three wastewater treatment plants (WWTPs) in Naples, Southern Italy, from January 2010 to December 2014. Influent and effluent samples from the three WWTPs were collected monthly. One hundred and sixty-one of the 731 wastewater samples collected (22.0%) before and after water treatment were CPE positive on RD cells; while no samples were positive on L20B cells from any WWTPs. Among the 140 non-polio enterovirus isolated from inlet sewage, 69.3% were Coxsackieviruses type B and 30.7% were Echoviruses. Among these, CVB3 and CVB5 were most prevalent, followed by CVB4 and Echo6. The twenty-one samples tested after treatment contained 6 CVB4, 5 CVB3, 3 Echo11, and 2 Echo6; while other serotypes were isolated less frequently. Data on viral detection in treated effluents of WWTPs confirmed the potential environmental contamination by HEVs and could be useful to establish standards for policies on wastewater management.
Collapse
Affiliation(s)
- Francesca Pennino
- Department of Public Health, University of Naples "Federico II", Via Sergio Pansini No 5, 80131, Naples, Italy
| | - Antonio Nardone
- Department of Public Health, University of Naples "Federico II", Via Sergio Pansini No 5, 80131, Naples, Italy
| | - Paolo Montuori
- Department of Public Health, University of Naples "Federico II", Via Sergio Pansini No 5, 80131, Naples, Italy.
| | - Sara Aurino
- Department of Public Health, University of Naples "Federico II", Via Sergio Pansini No 5, 80131, Naples, Italy
| | - Ida Torre
- Department of Public Health, University of Naples "Federico II", Via Sergio Pansini No 5, 80131, Naples, Italy
| | - Andrea Battistone
- National Center for the Control and Evaluation of Medicines (CNCF), Istituto Superiore di Sanità, Rome, Italy
| | - Roberto Delogu
- National Center for the Control and Evaluation of Medicines (CNCF), Istituto Superiore di Sanità, Rome, Italy
| | - Gabriele Buttinelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Concetta Amato
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Maria Triassi
- Department of Public Health, University of Naples "Federico II", Via Sergio Pansini No 5, 80131, Naples, Italy
| |
Collapse
|
41
|
Burmester GR, Fiore S, Hu CC, Fay J, Lee EB, Genovese MC. 214 Efficacy and safety of switching from adalimumab to sarilumab in an open-label extensionof a phase III monotherapy trial in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2018. [DOI: 10.1093/rheumatology/key075.438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Gerd R Burmester
- Department of Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Berlin, GERMANY
| | - Stefano Fiore
- US Global Medical Affairs, Sanofi Genzyme, Bridgewater, NJ, USA
| | - Chih-Chi Hu
- Biostatistics and Programming, Sanofi, Bridgewater, NJ, USA
| | - Jon Fay
- Medical Affairs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
| | - Eun Bong Lee
- Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF
| | - Mark C Genovese
- Rheumatology Department, Stanford University Medical Center, Palo Alto, CA, USA
| |
Collapse
|
42
|
Faletti R, Gatti M, Bassano S, Finocchietti D, Fiore S, Colla L, Bergamasco L, Cassinis MC, Fonio P. Follow-up of acute pyelonephritis: what causes the diffusion-weighted magnetic resonance imaging recovery to lag clinical recovery? Abdom Radiol (NY) 2018; 43:639-646. [PMID: 28660334 DOI: 10.1007/s00261-017-1242-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
PURPOSE To analyze with diffusion-weighted magnetic resonance imaging (DW-MRI) the evolution and progress to resolution of acute pyelonephritis (APN) foci over a period of 3 months after onset. METHODS 30 women (age 22-51 years) with clinical, laboratory (white blood cell and C-reactive protein), and DW-MRI (4b-values 0, 50, 600, 1000 s/mm2) diagnosis of APN were prospectively enrolled. Two double-blinded radiologists evaluated the number of APN foci, and for each of them dimension (D), absolute diffusion coefficient (ADC), and its ratio R to the ADC of unaffected parenchyma. Signature of radiological recovery was focus no longer visible (DW-) and ADC of its site not inferior to the ADC of the unaffected parenchyma, i.e., R ≥ 0.9. Clinical and DW-MRI follow-ups (FU) were performed at 1 and 3 months. RESULTS At the acute stage (t 0), 187 APN foci were found, with ADC0 = 1.3 ± 0.2 × 10-3 mm2/s, R 0 = 0.65 ± 0.12, and D 0 = 14 ± 7.5 mm. By the 1-month FU (t 1), all patients had no symptoms and physiological laboratory values; despite this, only 80 (43%) foci were solved, increasing to 138 (74%) by at the 3-month FU. The ROC curve (AUC ≥ 0.80) identified R 0 ≤ 0.6 and D 0 > 15 mm as forecast of slow radiologic resolution. About 80% of foci unsolved at 1 month but with R 1 ≥ 0.8 and D 1 ≤ 10 mm reached solution at 3 months. CONCLUSIONS DW-MRI recovery of APN foci does not always coincide with clinical recovery. The evolution of an APN focus is shaped by its initial values R 0 and D 0. About half of the foci still visible at 1 month reached radiological resolution in the two following months.
Collapse
Affiliation(s)
- Riccardo Faletti
- Department of Surgical Sciences, Radiology Institute, University of Turin, Via Genova 3, 10126, Turin, Italy
| | - Marco Gatti
- Department of Surgical Sciences, Radiology Institute, University of Turin, Via Genova 3, 10126, Turin, Italy.
| | - Serena Bassano
- Department of Surgical Sciences, Radiology Institute, University of Turin, Via Genova 3, 10126, Turin, Italy
| | - Daniela Finocchietti
- SCDU Nephrology, Città della Salute e della Scienza, University of Turin, Turin, Italy
| | - Stefano Fiore
- Department of Surgical Sciences, Radiology Institute, University of Turin, Via Genova 3, 10126, Turin, Italy
| | - Loredana Colla
- SCDU Nephrology, Città della Salute e della Scienza, University of Turin, Turin, Italy
| | - Laura Bergamasco
- Department of Surgical Sciences, University of Turin, Turin, Italy
| | - Maria Carla Cassinis
- Department of Surgical Sciences, Radiology Institute, University of Turin, Via Genova 3, 10126, Turin, Italy
| | - Paolo Fonio
- Department of Surgical Sciences, Radiology Institute, University of Turin, Via Genova 3, 10126, Turin, Italy
| |
Collapse
|
43
|
Abstract
Summary
Background:
In health applications, and elsewhere, 3D data sets are increasingly accessed through the Internet. To reduce the transfer time while maintaining an unaltered 3D model, adequate compression and decompression techniques are needed. Recently, Grid technologies have been integrated with Web Services technologies to provide a framework for interoperable application-to-application interaction.
Objectives:
The paper describes an implementation of the Edgebreaker compression technique exploiting web services technology and presents a novel approach for using such services in a Grid Portal. The Grid portal, developed at the CACT/ISUFI of the University of Lecce, allows the processing and delivery of biomedical images (CT – computerized tomography – and MRI – magnetic resonance images) in a distributed environment, using the power and security of computational Grids.
Methods:
The Edgebreaker Compression Web Service has been deployed on a Grid portal and allows compressing and decompressing 3D data sets using the Globus toolkit GSI (Globus Security Infrastructure) protocol. Moreover, the classical algorithm has been modified extending the compression to files containing more than one object.
Results and Conclusions:
An implementation of the Edgebreaker compression technique and related experimental results are presented. A novel approach for using the compression web service in a Grid portal allowing storing and preprocessing of huge 3D data sets, and subsequent efficient transmission of results for remote visualization is also described.
Collapse
|
44
|
Sodin-Semrl S, Antico G, Mikus R, Lakota K, Varga J, Fiore S. Lipoxin A4 and Serum Amyloid a Differentially Modulate Phospholipase D in Human Fibroblast-Like Synoviocytes. EUR J INFLAMM 2017. [DOI: 10.1177/1721727x0900700102] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Lipoxin A4 (LXA4) and scrum amyloid A (SAA) are endogenous negative and positive modulators of inflammation, respectively. Both molecules bind the shared lipoxin A4 receptor (ALX) and elicit opposing effects on the production of inflammatory cytokines and matrix metalloproteinases. The aim of these studies is to examine the divergence of the intracellular signaling pathways triggered by lipid LXA4 (1 nM) and protein SAA (200 nM) ligands of ALX. Phospholipase D (PLD) is a phosphohydrolase enzyme that catalyzes the generation of phosphatidic acid (PA) from membrane phospholipids. Our results showed that in fibroblast-like synoviocytes, activation of PLD occurred only in response to LXA4, and not SAA. PA (30 μM) mimicked LXA4 and demonstrated inhibition of IL-8 production induced by SAA or interleukin-1β. In sharp contrast to LXA4, SAA confirmed the stimulation of IL-8 release as determined previously. Taken together, these findings suggest that two physiologic ligands sharing the common ALX receptor, LXA4 and SAA, differentially regulate the level of PLD activation and differentially modulate IL-8. These results may have important implications for understanding the regulation of inflammatory responses under physiologic and pathological conditions.
Collapse
Affiliation(s)
- S. Sodin-Semrl
- University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
| | - G. Antico
- University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
- Northwestern University Feinberg School of Medicine, Department of Pathology, Chicago, IL, USA
| | - R. Mikus
- University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
- University of Illinois at Chicago, Department of Medicine, Section of Rheumatology, IL, USA
| | - K. Lakota
- University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
| | - J. Varga
- University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
- Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, IL, USA; Present address
| | - S. Fiore
- University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
- Genentech Inc., Clinical Science Development ITGR, 1 DNA Way, M/S 211, S. San Francisco, CA, USA
| |
Collapse
|
45
|
Sodin-Semrl S, Spagnolo A, Mikus R, Barbaro B, Varga J, Fiore S. Opposing Regulation of Interleukin-8 and NF-kB Responses by Lipoxin A4 and Serum Amyloid a via the Common Lipoxin a Receptor. Int J Immunopathol Pharmacol 2017; 17:145-56. [PMID: 15171815 DOI: 10.1177/039463200401700206] [Citation(s) in RCA: 65] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Lipoxin A4 (LXA4) is a potent eicosanoid that inhibits IL-1β-induced activation of human fibroblast-like synoviocytes (FLS) via the LXA4 receptor (ALXR). Serum amyloid A (SAA) is an acute phase reactant with cytokine-like properties. SAA has been shown to bind the same seven transmembrane G protein-coupled receptor ligated by LXA4. Here we compared the inflammatory responses of lipid (LXA4) and peptide (SAA) ligands in human FLS via the shared ALX and characterized their downstream signaling. LXA4 induced stimulation of tissue inhibitors of metalloproteinase-2, whereas SAA induced interleukin-8 and matrix metalloproteinase-3 production. SAA up-regulated NF-kB and AP-1 DNA binding activity, while LXA4 markedly inhibited these responses after IL-1β stimulation. A human IL-8 promoter luciferase construct was transfected into CHO cells stably expressing ALXR in order to determine the role of NF-kB and/or AP-1 in the regulation of IL-8 gene expression. The NF-kB pathway proved to be the preeminent for the biological responses elicited by both ligands. These findings suggest that two endogenous molecules, targeting a common receptor, could participate in the pathogenesis of inflammatory arthritis by differentially regulating inflammatory responses in tissues expressing the ALXR.
Collapse
Affiliation(s)
- S Sodin-Semrl
- Section of Rheumatology, Dept Med, COM, University of Illinois, Chicago, IL 60607-7171, USA
| | | | | | | | | | | |
Collapse
|
46
|
Fontana S, Buttinelli G, Fiore S, Mulaomerovic M, Aćimović J, Amato C, Delogu R, Rezza G, Stefanelli P. Acute flaccid paralysis surveillance in bosnia and herzegovina: Recent isolation of two sabin like type 2 poliovirus. J Med Virol 2017; 89:1678-1681. [PMID: 28390186 DOI: 10.1002/jmv.24827] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Accepted: 03/19/2017] [Indexed: 11/06/2022]
Abstract
The WHO Regional Commission for the Certification of Poliomyelitis Eradication has recently indicated Bosnia and Herzegovina (B&H) as a high risk country for transmission, following importation, of wild poliovirus (WPV) or circulating vaccine-derived poliovirus (cVDPV). We analyzed data on Acute Flaccid Paralysis (AFP) surveillance between 2007 to 2016, and the trend of polio immunization coverage in B&H. The majority of AFP cases was recorded in 2016 suggesting an enhancement of the AFP surveillance activities. However, the decline in the immunization coverage, around 74%, and the isolation of two Sabin-like poliovirus type 2 strains, one of them close to a VDPV, require a particular attention in the area. Although B&H has successfully maintained its polio-free status since 2002 several challenges need to be addressed.
Collapse
Affiliation(s)
- Stefano Fontana
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Gabriele Buttinelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Mirsada Mulaomerovic
- Department of Epidemiology, Institute for Public Health of Federation Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina
| | - Jela Aćimović
- Department of Epidemiology, Public Health Institute of the Republic of Srpska
| | - Concetta Amato
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Roberto Delogu
- National Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy
| | - Giovanni Rezza
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Paola Stefanelli
- Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.,WHO Polio Regional Reference Laboratory, c/o Istituto Superiore di Sanità, Rome, Italy
| |
Collapse
|
47
|
Pellegrinelli L, Bubba L, Primache V, Pariani E, Battistone A, Delogu R, Fiore S, Binda S. Surveillance of poliomyelitis in Northern Italy: Results of acute flaccid paralysis surveillance and environmental surveillance, 2012-2015. Hum Vaccin Immunother 2017; 13:332-338. [PMID: 27929744 PMCID: PMC5328214 DOI: 10.1080/21645515.2017.1264726] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Although in the last years poliovirus (PV) transmission has been reported at the lowest levels ever recorded, the spread of virus from endemic countries endures; the high levels of immigration flows across the Mediterranean Sea jeopardize Italy for PV reintroduction. The World Health Organization (WHO) strategic plan for global poliomyelitis (polio) eradication indicates the nationwide surveillance of Acute Flaccid Paralysis (AFP) as the gold standard for detecting cases of polio. In addition, the Environmental Surveillance (ES), seeking the presence of PV and Non-Polio Enterovirus (NPEV) in sewage, is recognized as a powerful tool to confirm PV circulation in absence of AFP cases, especially in polio-free countries. Here we report the results of AFP surveillance (AFPS) and ES in Lombardy (Northern Italy) from 2012 to 2015. Forty-eight AFP cases were identified during the study period. No AFP case was caused by PV infection. NPEVs were identified in 6.3% (3/48) of AFP cases. The annual AFP incidence rate was 0.87/100'000 children <15 y in 2012, 1.42/100'000 in 2013, 1.02/100'000 in 2014, and 0.47/100'000 in 2015; according to WHO indicators, the sensitivity of AFPS was adequate in 2013 and 2014. Completeness of case investigation raised progressively during the study period to achieve the WHO standards in 2014 (92.3%) and 2015 (100%). Completeness of follow-up increased from 72.7% in 2012 to 100% in 2014. In the framework of the ES conducted in Milan, 268 wastewater samples were collected from 2012 to 2015 and no PVs were isolated. In contrast, NPEVs were detected in 65.3% (175/268) of samples. All NPEVs characterized belonged to enterovirus species B: echovirus type 11, 6 and 3 were the most frequently detected viruses, representing 29.1% (41/141), 20.6% (29/141) and 9.2% (13/141) of genotyped NPEVs, respectively. Keeping strong and encouraging both AFPS and ES is crucial to ensure that PV will not return unnoticed in Italy - as well as in other polio-free countries - and, as a final point, to achieve the global polio eradication goal.
Collapse
Affiliation(s)
- Laura Pellegrinelli
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| | - Laura Bubba
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| | - Valeria Primache
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| | - Elena Pariani
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| | - Andrea Battistone
- National Center for Immunobiologicals Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy
| | - Roberto Delogu
- National Center for Immunobiologicals Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy
| | - Stefano Fiore
- National Center for Immunobiologicals Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy
| | - Sandro Binda
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| |
Collapse
|
48
|
Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NMH, Hamilton JD. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther 2016; 18:225. [PMID: 27716324 PMCID: PMC5052933 DOI: 10.1186/s13075-016-1132-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Accepted: 09/20/2016] [Indexed: 12/17/2022] Open
Abstract
Background Interleukin 6 (IL-6) signaling plays a key role in the pathophysiology of rheumatoid arthritis (RA) and is inhibited by sarilumab, a human monoclonal antibody blocking the IL-6 receptor alpha (IL-6Rα). The effects of sarilumab plus methotrexate (MTX) on serum biomarkers of joint damage and bone resorption were assessed in two independent studies (phase II (part A) and phase III (part B)) of patients with RA with a history of inadequate response to MTX from the MOBILITY study (NCT01061736). Methods Serum samples were analyzed at baseline and prespecified posttreatment time points. Biomarkers of tissue destruction, cartilage degradation, and synovial inflammation were measured in part A; assessment of these markers was repeated in part B and included additional analysis of biomarkers of bone formation and resorption (including soluble receptor activator of nuclear factor-kB ligand (sRANKL)). A mixed model for repeated measures was used to compare treatment effects on change in biomarkers. Additionally, changes from baseline in biomarkers were compared between American College of Rheumatology 50 % responders and nonresponders and between patients who achieved or did not achieve low disease activity (LDA), separately by treatment group, at week 24. Results In part A, sarilumab 150 and 200 mg every 2 weeks (q2w) significantly reduced biomarkers of tissue destruction, cartilage degradation, and synovial inflammation at both 2 and 12 weeks posttreatment (p < 0.05 vs placebo). These results were replicated in part B, with markers of these damaging processes reduced at weeks 2 and 24 (p < 0.05 vs placebo). Additionally, sarilumab 200 mg q2w significantly reduced both sRANKL and sRANKL/osteoprotegerin ratio at week 24 (p < 0.01 vs placebo). Trends for reduction were noted for several biomarkers in patients who achieved LDA compared with those who did not. Conclusions Sarilumab plus MTX significantly suppressed biomarkers of bone resorption and joint damage, as compared with placebo plus MTX, in patients with RA. Additional work is needed to determine whether differences in biomarker profiles at baseline or posttreatment can identify patients who achieve improvement in disease activity. Trial registration ClinicalTrials.gov, NCT01061736, February 2, 2010.
Collapse
Affiliation(s)
- Anita Boyapati
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.
| | - Jérôme Msihid
- Sanofi R&D, 1 Avenue Pierre Brossolette, 91380, Chilly-Mazarin, France
| | - Stefano Fiore
- Sanofi US, 55 Corporate Drive, Bridgewater, NJ, 08807, USA
| | - Janet van Adelsberg
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA
| | - Neil M H Graham
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA
| | - Jennifer D Hamilton
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA
| |
Collapse
|
49
|
Affiliation(s)
- P. Conti
- Immunology Division, Institute of Experimental Medicine, University of Chieti, 66100 Chieti, Italy
| | - M. Reale
- Immunology Division, Institute of Experimental Medicine, University of Chieti, 66100 Chieti, Italy
| | - R. C. Barbacane
- Immunology Division, Institute of Experimental Medicine, University of Chieti, 66100 Chieti, Italy
| | - M. Bongrazio
- Immunology Division, Institute of Experimental Medicine, University of Chieti, 66100 Chieti, Italy
| | - M. R. Panara
- Immunology Division, Institute of Experimental Medicine, University of Chieti, 66100 Chieti, Italy
| | - S. Fiore
- Immunology Division, Institute of Experimental Medicine, University of Chieti, 66100 Chieti, Italy
| |
Collapse
|
50
|
Sodin-Semrl S, Spagnolo A, Barbaro B, Varga J, Fiore S. Lipoxin A4 Counteracts Synergistic Activation of Human Fibroblast-like Synoviocytes. Int J Immunopathol Pharmacol 2016; 17:15-25. [PMID: 15000862 DOI: 10.1177/039463200401700103] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Excessive production of interleukin-6 (IL-6) and metalloproteinases (MMPs) has been implicated in the pathogenesis of rheumatoid arthritis. Lipoxin A4 (LXA4) and transforming growth factor (32 (TGF-|32) have potential anti-inflammatory activities; these two mediators were tested to determine how they affect IL-1β-dependent release of IL-6 and MMPs in human fibroblast-like synoviocytes. The results revealed dramatic differences between the mediators: TGF-β2 acted synergistically with IL-1β to stimulate IL-6 protein levels, whereas LXA4 inhibited IL-6 expression in a dose- and time-dependent manner. Inhibition, by LXA4 was abrogated when cells were pre-incubated with antibody against the ALXR (Lipoxin A4 Receptor) TGF-β2 by itself had no significant effect on IL-6 or MMP levels. LXA4, at nanomolar concentrations, altered the MMP-1 and MMP-3 expression levels of IL-1β and TGF-β2 stimulated fibroblast-like synoviocytes. Furthermore, IL-1β and TGF-β2 up-regulated ALXR mRNA. These results demonstrate, for the first time, that ALXR mediate the effects of LXA4 on inflammatory responses after stimulation of fibroblast-like synoviocytes with IL-1β plus TGF-β2. These activities might constitute an important mechanism by which LXA4 regulates synovial fibroblast activation.
Collapse
Affiliation(s)
- S Sodin-Semrl
- Department of Medicine/Rheumatology, COM, University of Illinois, Chicago, IL 60607, USA
| | | | | | | | | |
Collapse
|